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ABSTRACT 
 
Effects of Probiotic Administration during Coccidiosis Vaccination on Performance and 
Lesion Development in Broilers. (August 2009) 
Anthony Emil Klein, Jr., B.S., Texas A&M University 
Chair of Advisory Committee: Dr. David J. Caldwell 
 
The principal objective of this investigation was to evaluate coccidiosis 
vaccination, with or without probiotic administration, for effects on broiler performance 
and clinical indices of infection due to field strain Eimeria challenge during pen trials of 
commercially applicable durations.  During trials 1 and 2, body weights of vaccinated 
broilers were reduced (P<0.05) compared to other experimental groups during rearing 
through the grower phase.  Final body weights, however, were not different among 
experimental groups at the termination of each trial.  Similarly, feed conversion in trials 
1 and 2 was increased (P<0.05) in vaccinated broilers during rearing through the grower 
phase when compared to non-vaccinated broilers.  Significant improvements (P<0.05) in 
feed conversion were measured in trials 1 and 2 in vaccinated broilers during the 
withdrawal phase of grow-out.  Probiotic administration significantly reduced (P<0.05) 
feed conversion during the withdrawal phase of trial 2.  During trial 3, body weights of 
broilers in the vaccine with probiotic (water) group were higher (P<0.05) at termination 
(d 44) than all other experimental groups and equivalent to the ionophore alone and 
ionophore with probiotic groups.  Similarly, cumulative mortality corrected feed 
conversion ratio (FCR) was lower (P<0.05) in broilers from the vaccine with probiotic 
iv 
 
 
(water) group compared to negative controls, and not different from FCR in ionophore 
administered broilers. 
 Trial 2 observations revealed body weight gains among vaccinated broilers that 
were significantly increased (P<0.05) during a seven day clinical field strain Eimeria 
challenge period compared to non-vaccinated broilers.  Both probiotic and vaccine 
significantly decreased (P<0.05) gross lesion scores in upper and mid-intestinal regions.  
A significant reduction (P<0.05) in gross lower intestinal lesion score was also observed 
in the vaccine alone group.  In Trial 3 general observations showed, broilers in the 
ionophore alone group were associated with higher (P<0.05) microscopic mid and lower 
intestine lesion scores when compared to broilers receiving vaccine or vaccine + 
probiotic.  These data suggest that co-administration of probiotic during coccidiosis 
vaccination results in performance parameters that are improved when compared to 
vaccination alone and indistinguishable from protection conferred by feeding an 
ionophore in the presence of field strain Eimeria.  
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CHAPTER I 
INTRODUCTION  
Avian coccidiosis is an enteric disease condition of commercial poultry caused 
by host-specific intracellular protozoa of the genus Eimeria.  Eight Eimeria species have 
been recognized to infect chickens which include Eimeria acervulina, E. maxima, E. 
mivati, E. tenella, E. brunetti, E. necatrix, E. mitis, and E. praecox (Conway and 
McKenzie, 2007).  All species parasitize the epithelial cells of the intestine causing 
pathological changes ranging from local destruction of the mucosal barrier and 
underlying tissues, to systemic effects such as blood loss, shock syndrome, and even 
death (Vermeulen et al., 2001).  Coccidiosis continues to be one of the most 
economically critical diseases of the industry exacting economic losses of around 800 
million dollars a year (Allen and Fetterer, 2002).  The bulk of these costs come from 
performance losses related to infection and the cost of anticoccidial drugs to control the 
disease.  As stated previously Eimeria is extremely host specific.  Consequently Eimeria 
species that infect chickens will not infect turkeys, other birds, or mammals, and vice 
versa (McDougald, 1998).  Coccidian parasites replicate via a precisely programmed life 
cycle that includes three phases: sporogony, merogony, and gametogony (Lillehoj et al., 
2000).  Once the oocyst is shed into the environment in the feces of the bird, it 
undergoes sporogony and  
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becomes the infected state know as a sporozoite.  Following sporogony, four sporozoites 
are contained within a single sporulated oocyst.  The oocyst is then ingested by the bird 
from the environment to repeat the life cycle in the intestine of the bird.  The rigid life 
cycle of coccidian parasites is a valuable diagnostic tool for identifying the species of 
Eimeria causing an infection (McDougald, 1998).     
 There are different control measures for coccidiosis available for use in the U.S. 
poultry industry today.  Two principal types of control measures are anticoccidial drugs 
and vaccination.  The use of anticoccidial drugs is not a new concept.  Growers in the 
industry have been using anticoccidials since the 1950’s (Danforth, 1998).  These drugs 
can be classified as either synthetic anticoccidials that are produced by chemical 
synthesis (chemicals) or ionophorous antibiotics (ionophores) that are produced by 
fermentation (Chapman, 1999).  These types of drugs are still the most commonly used 
control method for coccidiosis used by today’s grower.  Earlier studies have shown that 
many of the compounds that are currently available are no longer as effective against 
coccidiosis due to emerging drug resistance (Chapman, 1997).  Some anticoccidials also 
require a one, two, or three week withdrawal period from feed prior to slaughter.   
Although this withdrawal may result in savings with the cost of medication, it must be 
balanced against increased risk of losses due to coccidiosis if birds become infected 
(McDougald and Reid, 1997).  Many growers today use a shuttle system for 
administration of these anticoccidial drugs which entails feeding one medication in the 
diet for a certain period of time and then switching to another type of drug or 
vaccination, and then continuing this practice in cycles.  More recent studies have shown 
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that even with rotational “shuttle” programs for feeding anticoccidial drugs to minimize 
the development of drug-resistance in field strain Eimeria, resistance to once effective 
anticoccidials continues to develop on a widespread basis throughout the U.S. and world 
(Williams, 2005).  The potential for residues of anticoccidial drugs to be present in 
broiler meat is promoting a change in consumer preference towards more natural 
alternative treatments.  Consequently, vaccination is gaining interest among integrators 
or growers both from an economical and a consumer preference standpoint.   
Vaccines, like anticoccidial drugs, have been used as a coccidiosis control 
measure by the industry for decades, but improved vaccine efficacy seems to be a 
requirement before broad-based acceptance will be realized.  Different types of vaccines 
are available for use in the industry, including attenuated and non-attenuated variations 
as well as live and killed vaccines.  Killed vaccines usually elicit a poor immune 
response and provide only limited protection (Du et al., 2005).  Although the appropriate 
antigens are present in killed vaccines required to stimulate the immune system, the 
immune response is not protective because the vaccine is not invasive and does not 
replicate within the host.  Live vaccines, comprised of oocyst of various Eimeria species, 
are the only practical alternative to anticoccidial drugs for the control of coccidiosis in 
poultry (Chapman et al., 2002).  Live oocyst vaccines usually consist of live oocyst from 
a “cocktail” of Eimeria species.  These vaccines work by introducing a low-level 
infection aimed at stimulating mucosal immunity early in life, thus allowing protective 
immunity during a subsequent field strain challenge.  Live oocyst vaccination has been 
shown to generate increased weight gain, improved feed conversion, and reduce clinical 
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lesions associated with coccidial challenge in broilers (Danforth, 1998; Crouch et al., 
2003; Li et al., 2005).   
Vaccines are usually administered in the first week of rearing.  Administration of 
vaccine can be performed in several ways, which include feed and water applications, 
gel administration, and the most commonly used method, spray application using a 
vaccination (spray) cabinet at the hatchery (Williams, 2002).  All reports regarding 
vaccination have not been positive however, and those of reduced performance with 
vaccination as compared to anticoccidial usage have likely led to the present incomplete 
acceptance of vaccination as a means of coccidiosis control throughout integrated broiler 
production (Allen and Fetterer, 2002; Williams, 2002). 
An emerging area of interest related to broiler enteric health involves feeding 
probiotics to stimulate mucosal immunity and improve intestinal health (Dalloul et al., 
2003; Farnell et al., 2006).  Probiotics are naturally occurring bacteria or a combination 
of different types of bacteria that possess the potential to improve intestinal or gut health.  
Probiotic therapy or prophylaxis is a natural approach to improve intestinal health 
because these bacteria can be found, in some quantity, in the normal microflora of the 
host.  As stated earlier, coccidiosis can have major implications on enteric health in 
commercial poultry.  So given its vital role in animal health, modulation of gut mucosal 
immunity would seem an appropriate way to affect the economic impact of infectious 
enteric diseases (Dalloul et al., 2005).  Gut mucosal surfaces play a key role in the 
exclusion and elimination of potentially harmful dietary antigens and enteric 
microorganisms.  Feeding probiotics to poultry has been shown to maintain beneficial 
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intestinal microflora and may modulate the mucosal immune system enhancing the 
host’s resistance to enteric pathogens (Dalloul et al., 2003; Farnell et al., 2006).  Several 
studies have shown disease prevention or immune enhancement resulting from oral 
administration of probiotics in poultry (La Ragione, et al., 2004; Koenen et al., 2004).  
Several papers have also been published demonstrating protection against Eimeria 
acervulina infections in chickens when given a preventative treatment of probiotic 
bacteria (Dalloul et al., 2003; Dalloul et al., 2005).  The probiotic approach would also 
be considered more natural then medication control measures, and with consumer trends 
shifting in this direction, probiotics could be a viable alternative to anticoccidial drugs.  
Probiotics alone have been shown to benefit the host, but to date investigation into the 
effects of probiotics on the efficacy of coccidiosis vaccination has not been performed.  
The principal objective of this body of research was to investigate whether a 
Lactobacillus-based probiotic could improve live oocyst coccidiosis vaccination efficacy 
when administered to broilers under simulated commercial rearing conditions.  
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CHAPTER II 
LITERATURE REVIEW 
 
History and Life Cycle 
Coccidia consist of a wide variety of single celled, parasitic animals in the 
subkingdom Protozoa of the phylum Apicomplexa (Conway and McKenzie, 2007).  This 
phylum consist of all protozoa that possess an apical complex, which by definition is an 
assembly of organelles located at the anterior end of certain life cycles stages that 
facilitate attachment and or entry into the host cell (Current et al., 1990).  Within this 
phylum are two suborders known as Adeleorina and Eimeriorina.  Eimeria, which is a 
pathogen of concern to commercial poultry, belongs to the suborder Eimeriorina which 
consists of 10 families, 37 genera, and around 1500 named species (Levine, 1982).  
Records show that the first coccidia were studied in 1674 when Leeuwenhoek found 
oocysts of Eimeria stiedai in rabbit bile.  Coccidia were not actually described until 1839 
by Hake when he thought he found a new form of puss globule (Levine, 1982).  Later in 
1865, Lindemann named them Monocystis stiedae. Finally, after many changes to the 
name, in 1913 Poche called it Eimeriorina which is accepted today (Levine, 1973).   
As described above, there are many genera of parasitic protozoa belonging to the 
phylum Apicomplexa and among those is the genus Eimeria.  The first avian Eimeria life 
cycle was described in 1910 and the organism was named Eimeria avium (Yabsley, 
2008).  Avian coccidiosis is an enteric disease condition of commercial poultry caused 
by host specific intracellular parasitic protozoa of the genus Eimeria.   To date, around 
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200 species of Eimeria have been described to infect avian species (Yabsley, 2008).  
Eight Eimeria species have been recognized to infect chickens, including Eimeria 
acervulina, E. maxima, E. mivati, E. tenella, E. brunetti, E. necatrix, E. mitis, and E. 
praecox (Conway and McKenzie, 2007).   
Coccidian parasites, including Eimeria species, replicate via a precisely 
programmed life cycle that includes three phases: sporogony, merogony, and 
gametogony (Lillehoj et al., 2000).  This life cycle also includes parasitic and non-
parasitic stages.  The life cycle stages consist of two asexual (sporogony,merogony) 
stages and one sexual (gametogony) stage of reproduction.  The parasitic stage begins 
with the sporulated oocyst which exists in the environment (McDougald and Reid, 
1997).  The life cycle begins when the infective stage or sporulated oocyst is ingested by 
the bird.  Once ingested, mechanical and chemical (trypsin and bile) actions in the gut 
break down the oocyst wall and release sporocysts, then sporozoites into the duodenal 
lumen of the gastrointestinal tract (McDougald and Reid, 1997).  Sporozoites invade the 
intestinal lining of epithelial cells and then proceed into merogony.  In the merogony 
stage of the life cycle, the sporozoites become what are known as first generation 
meronts.  Each meront then, through multiple fission, forms around 900 first generation 
merozoites (Levine, 1982).  Merozoites then enter the lumen of the intestine about two 
to three days after first inoculation.  Form this point some merozoites begin to reinvade 
the intestinal epithelium to continue the life cycle, while others continue with the further 
stages of asexual reproduction.  After four or five days, the merozoites form around 250-
300 second generation merozoites, while some enter new intestinal cells in order to form 
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third generation meronts which produce anywhere from four to 30 third generation 
merozoites (Levine, 1982).  After repeated cycles of asexual merogony, other merozoites 
enter the host cell in order to begin the sexual phase of the lifecycle known as 
gametogony.  Gametocytes in this stage develop intracellularly into macrogametocytes 
(female) and microgametocytes (male).  From here, microgametocytes produce many 
microgametes which are flagellated and motile so that they can migrate to the 
macrogametocytes for fertilization (Vetterling and Doran, 1966).  Macrogametocytes 
developed into a macrogamete and can then be fertilized by the motile microgametes.  
Upon fertilization, the macrogamete develops into a zygote and finally to an oocyst.  The 
oocyst is very durable and resistant mostly because of its durable outer wall.  This is 
developed during the entire life cycle by intracytoplasmic granules located peripherally 
that eventually unite to form the outer wall (Levine, 1982).   
An important feature of the life cycle of avian Eimeria is that the prepatent 
period is extremely rapid.  From the time of ingestion to the time the oocyst is back into 
the environment is only 5-7 days, depending upon species.  The multiplication of oocysts 
can occur at a rate of anywhere from 1,000 to 1 million oocysts from one ingested oocyst 
(Chapman, 1993).  The rate of oocyst production from one ingested oocyst varies from 
species to species.  Once the oocyst is in the environment, sporulation can occur through 
a process called sporogony.  In order for sporulation to occur the proper environmental 
conditions must be present including sufficient oxygen, temperature (72 to 90F), and 
moisture content (Relative Humidity around 30%).  Once the oocyst is passed through 
the feces into the environment it contains a single celled, diploid sporont.  In the 
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presence of oxygen, the cell undergoes reduction division and a polar body is thrown off 
(Levine, 1982).  Now the cell is haploid and it divides into four sporoblasts.  Each 
sporoblast then turns into a sporocyst containing two sporozoites (Levine, 1982).  When 
the oocyst reaches this stage of the life cycle it becomes a sporulated oocyst.  This 
process usually takes one to two days in the environment under ideal conditions.  After 
sporulation, the oocyst can then be ingested by the animal to repeat the life cycle once 
again.  The characteristic cell wall of an Eimeria oocyst makes it extremely hard to 
eliminate during sanitation.  It takes extreme heat to kill a sporulated oocyst in the 
environment and oocysts are inherently resistant to chemical treatments.  
 
Site Specificity and Immunity 
As mentioned previously, Eimeria species are extremely host specific enteric 
pathogens.  Chicken Eimeria are also site or location specific within the gut, causing 
damage to different sections of the intestine depending on which species has invaded the 
host.  This characteristic of Eimeria infection in commercial poultry represents a 
valuable tool for field diagnosis of coccidiosis cases.  The most commonly diagnosed 
infections in poultry are those consistent with Eimeria acervulina, E. maxima, and E. 
tenella derived from heavily populated commercial rearing farms (McDougald et al., 
1997).  Eimeria acervulina and E. mivati are site specific to the duodenum or most 
cranial part of the gastro intestinal tract (Witlock and Ruff, 1977).  The mid gut is 
parasitized and lesions are formed by E. maxima and E. necatrix, while the highly 
pathogenic E. tenella and E. brunetti cause lesions in the ceca and large intestine (Kogut, 
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1990).  E. acervulina is possibly the most common species found in domesticated fowl. 
The life cycle of this species contains 4 asexual generations of meronts.  The parasite 
usually attacks the epithelial cells of the villi, but in some cases it can be found in 
glandular cells of the upper intestine (Joyner, 1982).  This species is usually considered 
mild to moderately pathogenic.  Meronts of E. maxima usually develop in the epithelial 
cells of the villi of the small intestine, and is considered the most immunogenic species 
of Eimeria that is known to infect chickens (Rose and Long, 1962; Joyner, 1982; 
Chapman et al., 2005).  Two asexual generations of meronts are common with E. 
maxima (Joyner, 1982).  Perhaps the most pathogenic strain of Eimeria known to infect 
chickens is E. tenella.  This species parasitizes the villar epithelial cells and the 
submucosa of the ceca.  Eimeria tenella is also recognized to have three asexual 
generations of meronts and is associated with hemorrhagic enteritis and even death in 
young chicks (Joyner, 1982).  All species of chicken Eimeria parasitize the epithelial 
cells of the intestinal lining causing pathological changes ranging from local destruction 
of the mucosal barrier and underlying tissues, to systemic effects such as blood loss, 
shock syndrome, and even death (Vermeulen et al., 2001). 
Eimeria infections are generally associated with varying degrees of malaise, 
nutrient malabsorption, reduction of growth rate, and reduced intestinal viscosity 
depending on the species infecting the host (Allen and Fetterer, 2002).  Common signs 
of infection include bloody or watery diarrhea, morbidity, poor digestion, bloody or 
soiled vent, and mortality.  When the oocyst wall is broken down following ingestion, 
sporozoites begin to parasitize mucosal and submucosal epithelial cells of the intestine.  
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The immune response of the chicken to Eimeria species is very complex and involves 
innate and adaptive mechanisms.  Primary and secondary infections of Eimeria species 
will stimulate an acquired response that involves both cell mediated and humoral 
immune components (Lillehoj and Trout, 1996).  Since Eimeria during an infection 
parasitize the intestinal mucosa, the first line of defense is the gut associated lymphoid 
tissue or GALT.  Birds lack the classic well defined lymph nodes found in mammals, 
therefore the GALT has to represent a principal site of coordination for adaptive and 
innate immune response (Caldwell et al., 2004).  The GALT is located above the 
basement membrane and contains many cells including epithelial, lymphoid, Natural 
Killer (NK) cells, and other antigen presenting cells which can be found in cecal tonsils, 
Peyers patches, and the bursa of Fabricius (Lillehoj and Trout, 1996).  The lamina 
propria is located below the basement membrane and contains the submucosa and 
lymphoid tissue (Yun et al., 2000).  The GALT is generally associated with three 
functions involved in host defense against coccidiosis.  These include antigen processing 
and presentation, production of intestinal antibodies, and activation of cell mediated 
response (Brandtzaeg et al., 1987).   
Peyer’s patches are specialized lymphoid organs found in the GALT of the 
domestic fowl.  They consist of lymphoid tissues that provide a microenvironment for 
lymphocytes and antigen to interact (Burns, 1982).  Peyer’s patches contain B-cells, T-
cells, and antigen presenting cells as well as Microfold cells (M-cells) that allow for 
antigen uptake from the lumen for inducing immune responses (Yun et al., 2000).  Cecal 
tonsils are structures located at the ileo-cecal junction of the chicken and serve as a B-
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cell and T-cell storage site to allow for transport to areas of the body when signaled for 
immune response (Befus et al., 1980; Glick et al., 1981).  Stimulation from contact with 
continuous new foreign antigen can be achieved here due to the continuous backflow 
from the urodaeum of the cloaca to the cecal tonsils.  Birds have a unique structure 
known as the bursa of Fabricius that is the central organ of B-cell maturation, B-cell 
lymphoiesis, and antibody diversity generation (Ratcliffe, 1989).  All three of these 
structures are associated with the GALT and play a key role in immune response to the 
invading parasite. 
Epithelial cells of the various intestinal regions, described above, are the host 
cells for parasite invasion and replication.  These cells obviously also serve as the 
principle absorptive cells for nutrients obtained from the digesta of the bird.  When 
pathogens are present in the intestinal tract, these cells come in contact with the 
pathogen and then generate cell death after ingestion of the parasite to try and rid the 
body of the invading parasites (Yun et al., 2000).  More recently epithelial cells have 
been described as sources of cytokines and other chemicals involved in immunity to 
invading pathogens (McGee et al., 1993; Reinecker et al., 1996).  Once an epithelial cell 
is invaded by a pathogen several documented cytokines including IL-1, IL-6, IL-8, 
TNFα are produced (Keelan et al., 1998).  These cytokines and other chemicals play an 
important role in innate and adaptive immunity by contributing to inflammation during 
the immune response.  Although not generally classified as professional antigen 
presenting cells, intestinal epithelial cells have been shown to express MHC class I and 
II molecules.  This allows them to present antigen to not only CD8+ T-cells but also 
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CD4+ T-cells (Kaiserlian et al., 1989).  The overall function of epithelial cells in 
resisting coccidiosis infection is not completely understood, but the basis to responses to 
other invading intestinal pathogens suggests that they are important in immune responses 
to coccidia.  
Once the parasite has been recognized in the host, the innate immune system 
begins the initial response.  Innate immunity is responsible for destruction of parasite 
during the early phases of the primary infection (Lillehoj and Trout, 1994).  Among the 
first responders are macrophages which possess the proper MHC complex on their 
surface for presentation to B and T lymphocytes during active immunity (Dalloul and 
Lillehoj, 2006).  They also express co-stimulatory molecules (B7-1 and B7-2) which 
amplify T-cell activation (Yun et al., 2000).  Macrophages also have the capacity to 
secret a broad array of cytokines which up regulate immune responses (Dalloul and 
Lillehoj, 2006).  Vainio and Lassila (1989) found that chickens that ingested E. 
acervulina oocysts also had significant numbers of sporozoites within macrophages that 
responded to the infection.  Macrophages were also shown to secret large amounts of 
TNFα upon stimulation by ingested sporozoites (Zhang et al., 1995).  These cells thereby 
induce inflammation at the site of infection which contributes to the severity of the 
infection.  Macrophages play an important role in both innate and active immune 
response to invading pathogen of the intestine (Dalloul et al., 2007). 
Since these parasites are intracellular by nature and are generally ingested by 
responding cells, NK cells also play an important role in innate immune response.  NK 
cells are phenotypically similar to CD8+ T cells but lack the ability to be antigen 
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specific.  These cells of the innate system are derived from lymphocyte lineage and are 
usually characterized by a large granular morphology in the cytoplasm.  NK cells kill 
target cells in similar fashion to CD8+ T cells but are not restricted to MHC antigen 
recognition (Bancroft, 1993).  The effects of the NK cells on the invading parasite are 
controlled by several mechanisms.  These include secretion of cytokines (IFNγ), lysis of 
infected host cells, and direct inhibition of growth of microorganisms through 
interactions with T-cells (Bancroft, 1993).  Besides being able to kill invading cells, the 
production of IFNγ by NK cells plays an important role in macrophage stimulation 
(Perussia, 1991).  NK cell presence is also associated with an increase in lymphocytes 
that express CD8+ receptors within the infected epithelial cells (Lillehoj and Bacon, 
1991).  Therefore, they are believed to be involved in cell mediated as well as innate 
immune mechanisms directed against Eimeria.  
Other cells likely involved in innate immunity to coccidial infection are mast 
cells.  Mast cells have very important characteristics that aid in destruction of parasitized 
cells.  These include secretion of pro inflammatory and anaphylactic mediators as well 
as the ability to release these mediators in multiple cycles to provide response over a 
long period of infection (Abraham and Arock, 1998).  The exact role of mast cells in the 
innate immune response is not well known however they do seem to play a role.  
Caldwell and colleagues (2004) have shown the mucosal mast cell population has 
increased during periods of Eimeria challenge.  Avian mast cells contain mediators such 
as histamine and serotonin that stimulate degranulation and hypersensitivity response 
(Rose et al., 1980).  Degranulation of mast cells in response to infection could be 
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associated with the diarrhea that often accompanies some Eimeria infections.  Morris 
and colleagues (2004) noted an increase in mast cell presence during infection with E. 
acervulina as well as an increase in anaphylactic secretary action that can be associated 
with mast cell response and degranulation.  Mast cells are also thought to be involved in 
the immune response to Eimeria however; more research needs to be done to identify the 
exact role of these cells in protective immune responses.  
The adaptive immune response is the second phase of a complete immune 
response to a foreign antigen.  Coccidiosis infections induce a response from both 
humoral and cell mediated systems in order to protect the chicken’s intestinal tract from 
the infection.  B and T lymphocytes are, as described earlier, located within intestinal 
epithelial cells and in the lamina propria of the GALT of the chicken.  Although both 
cell mediated and humoral responses are present, it has been well documented that the 
cell mediated responses seems to be the primary mechanism for resolving coccidiosis 
infections in chickens (Lillehoj and Trout, 1996; Yun et al., 2000; Lillehoj and Lillehoj, 
2000).  
The role of T-cells in response to coccidial infection in chickens has been 
investigated thoroughly throughout the years.  The presence of Eimeria infection has 
been associated with an increase in CD4+, CD8+, and γδ TCR in the intestine of the bird 
(Bessay et al., 1996).  T-cells are separated into CD4+ (helper/inducer/regulatory) T-
cells and CD8+ (cytotoxic) T-cell sub-types.  These classes can also be separated by the 
types of T-cell antigen receptor (TCR) expressed, which include αβ or γδ TCR.  CD8+ T 
cells recognize antigen from MHC class one molecules while CD4+ T-cells recognize 
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antigen from MHC class two molecules.  CD8+ T-cells seem to be the most common 
responding cell in the presence of Eimeria parasites.  One study revealed during a 
characterization of the peripheral blood that 75-80% of the circulating lymphocytes were 
CD8+ T-cells while 5-15% were CD4+ T-cells during Eimeria infection, with the 
majority of the CD8+ T-cells expressing γδ TCR (Selby et al., 1984).  Since Eimeria 
parasites are ingested, γδ TCR CD8+ T-cells are poised for immediate contact as the vast 
majority of this phenotype of T-cell is found within IECs of the chicken.  During 
coccidial infection, CD4+ T-helper cells likely aid in antibody synthesis during humoral 
responses and assist in delayed type hypersensitivity reactions.   
Eimeria infection in chickens has been shown to result in the production of 
antigen specific IgA, IgM, and IgY in mucosal secretions.  The intestine is the largest 
immunological organ of the chicken’s body, containing 70 to 80% of the total 
immunoglobulin producing cells, and more secretory IgA than the total production of 
IgG (Yun et al., 2000).  Secretory IgA (sIgA) has been shown to stimulate immunity and 
provide protection to various enteric pathogens (Ganguly and Waldman, 1980).  During 
coccidiosis, Eimeria-specific antibodies may actually have more of an indirect role on 
parasitic infection.  Suggested roles in protective immunity include parasite 
agglutination, neutralization, causing changes in parasite host cell receptor molecules, 
and by inhibition of intracellular parasite growth and development (Lillehoj and Lillehoj, 
2000).  
Cytokines are one of the most important components of a complete immune 
response in the chicken to coccidial infection.  Cytokines are released by various cells 
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throughout the immune response and are important in regulating both innate and 
adaptive responses.  IFNγ is secreted by Th1 CD4+ T-cells and NK cells and participates 
in innate immunity through stimulation of proliferation and differentiation of 
hematopoietic cells (Lillehoj and Lillehoj, 2000).  Macrophage activation is also 
stimulated by IFNγ which improves the cytolytic activity of the macrophage.  Other 
noted cytokines that are secreted during coccidiosis infection include TNFα, TGFβ, IL-1, 
and IL-15.  TNFα is secreted by macrophages and is associated with reduction in 
parasite pathogenesis and the development of protective immunity (Byrnes et al., 1993).  
TGFβ may induce growth of intestinal epithelial cells and villi which can aid in recovery 
and subsequent protection from the infection (Byrnes et al., 1993).  IL-15 promotes γδ 
TCR expression on the CD8+ T-cell, which assists in cell mediated responses, and is 
known to promote NK cell proliferation and activation (Choi et al., 1999).  Despite 
significant advances in recent years, complete immunity to Eimeria infection is not 
completely understood.  A better understanding could aid in the efforts to develop 
alternative and more effective methods of control.  
 
Coccidiosis Control Measures-Anticoccidials 
The most commonly used method of controlling Eimeria infections in 
commercial poultry is prophylactic chemotherapy through the use of dietary 
anticoccidial drugs.  The first true anticocidials, known as sulphonamides, were 
introduced to the poultry industry during the 1940’s (Chapman, 1999).  Over the past 60 
years, anticoccidial drugs have made a major contribution to the growth of the poultry 
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industry due to the effectiveness of the drugs in controlling coccidiosis (Allen and 
Fetterer, 2002).  The two most commonly used types of anticoccidials are synthetic 
anticoccidials produced by chemical synthesis and ionophorous antibiotics (ionophores) 
that are produced by fermentation.  Synthetic or chemical anticocidials usually have a 
specific mode of action on parasite metabolism, while ionophores act through a general 
mechanism of altering membrane ion transport causing a disruption of osmotic balance 
(Chapman, 1999;  Allen and Fetterer, 2002).  Examples of chemical or synthetic 
anticoccidials are amprolium, clopidol decoquinate, nicarbizin, and halofuginone, while 
some commonly used ionophores include monensin, salinomycin, narasin, and 
maduramycin.  Of the two classifications of anticoccidials, ionophores tend to be the 
most frequently used by the U.S. broiler industry due to the fact that they have a broad 
spectrum of activity and are coccidiocidal in action (McDougald, 1990).  In general most 
drugs used for control of Eimeria are extremely effective against some species but not 
very effective against others.  As a result, combinations of different drugs may be used 
to generate better control of the parasite within commercial operations. 
Chemical anticoccidial drugs work by acting on specific stages of the Eimeria 
life cycle.  Most drugs act upon the asexual stages of the Eimeria lifecycle (Chapman, 
1993).  Ionophores used in coccidiosis control typically target sporozoites, but 
merozoites can be affected if they come in contact with the drug.  Ionophores do not 
work as well during in vitro laboratory tests, but in vivo they seem to be the most 
effective form of control causing significant damage to the parasite (McDougald, 1990).  
The ionophorous drug acts on the sporozoites by facilitating the actions of inorganic 
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cations across the cell membrane interrupting important physiological functions such as 
balance of sodium and potassium (McDougald, 1990).  Chemical anticoccidials in 
general effect the latter stages of the life cycle of Eimeria species.  One example is the 
mode of action of amprolium, which disrupts normal function of the parasite by blocking 
the transport of thymine across the cell membrane (Chapman, 1993).  Though not 
deemed as successful as ionophores, chemical anticoccidial drugs are still used regularly 
in the industry.  
Despite the success of anticoccidials for controlling coccidiosis in commercial 
environments, certain drawbacks have been associated with continued drug usage 
throughout the years.  The primary concern is drug resistance of field strain Eimeria due 
to repeated exposure to anticoccidials.  Drug resistance has been a concern ever since the 
introduction of anticoccidial drugs in the 1940’s.  It has been well documented that 
growing resistance of Eimeria species to anticoccidial drugs has occurred over the past 
several decades (Jeffers, 1974; Chapman,1986; McDougald, 1990) including more 
recent studies showing resistance in Nicarbazin-containing anticoccidials( Bafundo et 
al., 2008).  Resistance at some level has been identified in all forms of anticoccidials that 
have been used for control of coccidiosis in the poultry industry (Chapman, 1994).  
Resistance has been associated with the Eimeria species changing levels of sensitivity to 
continuously used drugs including the extensively used ionophorous drugs (McDougald, 
1981).  Another downside to anticoccidial use is that some require a mandatory 
withdrawal period from poultry feed prior to slaughter due to the possibility of residual 
drug being passed to carcasses entering the retail market.  Other concerns stem from 
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animal welfare-related issues.  An example includes the use of nicarbazine and products 
containing nicarbizine.  Nicarbizine is known to have an extremely broad spectrum of 
anticoccidial activity and can potentiate the activity of ionophorous anticoccidial drugs 
(Bafundo et al., 2008).  It also causes heat stress in commercial poultry when used in 
broilers that are reared in climates with higher temperatures, as are common in the 
southern United States during the summer months (McDougald, 1990).   
There have been studies conducted which have tested the effect of the 
withdrawal period on disease outbreak.  One thought is that reduced sensitivity to drugs 
may actually help birds obtain immunity. Using a drug that is known to be effective 
against certain species of Eimeria but not others could allow for mild exposure to the 
pathogen allowing for immune stimulation even in the presence of anticoccidial drugs, 
which may allow for a long term withdrawal period (Chapman, 1999).  However other 
studies have shown that obtaining immunity in the presence of anticoccidial drugs could 
take as long as seven weeks (Chapman, 1999; Chapman et al., 2004).  If true, such 
observations present an obvious problem to broiler integrators since most grow-out 
programs for commercial broilers only last at most between six and eight weeks.  Most 
regulations on anticoccidial withdrawal periods call for the drug to be pulled at least one 
week before slaughter.  If immunity is not established by this point and the birds are 
exposed to Eimeria during late-phase production, they will become infected and possibly 
experience performance loss from the infection.  Ideally, the most effective method of 
control while using anticoccidial drugs would be achieved through medication 
throughout the entire rearing process.  As described above, this is not possible for most 
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anticoccidials used in the U.S. due to mandatory withdrawal regulations in place.  
Another complication of continual usage would be the likely acceleration of the 
emerging pattern of drug-resistance among field strain Eimeria. 
The most commonly recommended control measures for coccidiosis are 
strategies involving anticoccidial usage with shuttle or rotation programs (McDougald et 
al., 1986; Vermeulen et al., 2001; Peek and Landman, 2006).  Shuttle programs call for 
the use of one drug for the first 21-28 days of grow-out before switching to another drug 
for the remainder of rearing.  A rotation program consists of one drug or combination of 
drugs for a certain period of time throughout the year, followed by a switch to 
vaccination and then continuing this cycle.  The rotation program can be applied on a 
timeline of anywhere from every six months to as long as two years (Levine, 1982).  The 
purpose of these two types of programs is to allow for control while trying to avoid or 
counteract drug resistance.  Studies have shown that resistance is stable and almost 
impossible to avoid, but the loss of resistance may occur when a drug is not used for a 
period of time (Chapman, 1993).  This phenomenon is thought to be the result of the 
presence of drug resistant and drug sensitive strains co-populating the rearing 
environment, where as the drug resistant strain becomes the predominate strain in the 
population (Long et al., 1985).  It has also been stated that since many of the 
anticoccidials have a similar mode of action, they could also share common resistance 
when used in the field (Chapman, 1993).  The mechanisms involved in the spread of 
drug resistance are not completely understood and there have not been many studies 
investigating the length of time it takes for an Eimeria species to become resistant to 
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drugs (Williams, 2006).  Increased consumer awareness to the use of medication in 
poultry feed will presumably demand that broilers be reared using minimal feed 
additives and medication in the near future (Vermeulen et al., 2001).  Eventually poultry 
producers will have to find alternative control measures for coccidiosis to comply with 
these restrictions.  
 
Control Measures-Vaccination 
 As a result of the continued pattern of drug resistance developing in field-strain 
Eimeria species, there is increasing interest in developing alternative control measures to 
combat coccidiosis infection.  Vaccination with live Eimeria oocysts is a viable 
alternative to prophylactic anticoccidial control and vaccination has been proven 
successful in commercial settings (Danforth, 1998).  The use of vaccines as a control 
measure for avian coccidiosis is not a new concept and has been used since the 1950’s 
(Edgar, 1958; Shirley and Bellatti, 1988).  The ability for chickens to become resistant to 
parasite infection after previously being exposed to the same parasite has been well 
documented (Gilbert et al., 1988; Augustine et al., 1991; Stiff and Bufando, 1993; 
Lillehoj and Trout, 1994; Williams, 1998).  The purpose of vaccination is to expose the 
host to low numbers of the parasite in order to stimulate protective immunity against 
parasitic infection later on in life (Lillehoj and Trout, 1994).  Live vaccines used in the 
poultry industry typically include several species and strains of Eimeria typically 
isolated from commercial poultry production facilities that can either be attenuated (egg-
adapted and/or precocious lines) or non-attenuated (Danforth, 1998).  
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 Attenuated vaccines in the past have been more appealing to growers because 
the strains used for vaccination are not as virulent as those used in non-attenuated 
vaccines.  Attenuation generally involves repeated passage in vivo of a virulent strain of 
the parasite and the subsequent selection of early maturing, less pathogenic, or 
precocious strains (McDonald and Ballingall, 1983).  Once a precocious strain as been 
selected, the prepatent period of the parasite is decreased due to the reduced generations 
of merogony, resulting in a reduction in virulence of the parasite (Lillehoj et al., 2000).  
Another more recently explored method for attenuating Eimeria species is irradiation.  
Sporozoites from sporulated Eimeria oocysts exposed to gamma irradiation are 
apparently still capable of infecting the host, but asexual development of the parasite in 
the host seems to be reduced (Jenkins et al., 1997), thus reducing the virulence of the 
parasite.  Egg passage or in vivo embryo passage of Eimeria has also been used for 
attenuation.  While some species showed a reduction in virulence after passage, other 
species were not amenable to this process (Innes and Vermeulen, 2006).  Other methods 
of attenuation, including inoculating isolated and in vitro cultured parasites from 
different regions of the intestine in order to stimulate immunity, have been studied 
(Lillehoj et al., 2000) but success has not been common.  In theory, attenuated vaccines 
would be successful in stimulating immunity without the risk of performance loss 
associated with more virulent non-attenuated vaccines.  Aside from fewer reports of 
efficacy, other negative aspects of attenuated vaccines include the higher production cost 
associated with the vaccine (Dalloul and Lillihoj, 2005).  Furthermore, a study 
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conducted by Crouch and colleagues (2003) noted that the broilers receiving an 
attenuated vaccine did not perform as well as broilers receiving anticoccidial medication.   
The second classification of live oocyst vaccines available for use in the U.S. 
poultry industry is the non-attenuated type.  Vaccines categorized as non-attenuated are 
comprised of live Eimeria species obtained from the field or laboratory which have not 
been changed in any way, and typically possess drug sensitivity to commonly used 
anticoccidials (Dalloul and Lillihoj, 2005).  Live non-attenuated vaccines usually contain 
various species of Eimeria depending on the vaccine. For example, broilers are reared 
for short duration grow-out periods and usually don’t need protection against the less 
common species, so vaccines designed for broilers may only include field strains of E. 
maxima, E. acervulina, and E. tenella (Chapman et al., 2005).  Live non-attenuated 
vaccines have been used regularly, but raise some concerns among growers because of 
the risk of early performance loss.  Importantly, vaccines of this type typically stimulate 
protective immunity to various Eimeria species (Shirley and Millard, 1986; Long et al., 
1986; Bedrnik et al, 1989; Shirley, 1989).  
 Live oocyst vaccines have been used for many years, but a common complication 
to vaccination exists with methods for applying the vaccine to large numbers of animals 
in a cost-effective, management-feasible, fashion.  In order to vaccinate with live oocyst 
vaccines, growers need an efficient and economically feasible method that will inoculate 
all birds with a low number of oocysts, while assuring that every chick is receiving the 
correct dose (Danforth, 1998).  Some of the earlier methods explored  for live oocyst 
vaccine administration included spraying vaccine directly on the feed or delivering 
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orally through a medication tank connected to the watering system (Dalloul and Lillehoj, 
2005).  Another method that was explored involved inoculating chicks through a 
spraying mechanism directly into the eye.  The idea was the oocyst would travel down 
the nasolacrimal duct and pass to the intestine through the oropharanx.  While deemed 
effective, this method required highly trained personnel and was not considered feasible 
by the U.S. poultry industry (Dalloul and Lillihoj, 2005).  Immucox® is a live oocyst 
vaccine used by the industry that is administered as a colored gel placed in chick trays or 
in feeders at day of hatch for the chicks to ingest.  During an investigation of four 
methods of vaccine delivery, gel administration in this fashion was determined to be the 
most effective route of administration (Danforth, 1998).  While not feasible due to 
intense labor requirements, the most effective route of administration of a vaccine for 
achieving uniform exposure would be through oral gavage of each individual chick with 
live oocysts (Chapman et al., 2002).  This method would not be economically possible 
with the number of birds reared in the United States each year.  Administration of live 
oocyst coccidiosis vaccines in broiler hatcheries is most commonly performed using a 
spray cabinet delivery system (Augustine et al., 2001).  This method, used most 
extensively for viral vaccination, has been modified for live oocyst coccidiosis vaccines 
(Chapman et al., 2002).  Spray cabinet vaccination can be done quickly and is an 
economically plausible method of vaccination, but there are efficacy issues associated 
with this method, such as proper dosage uptake for each individual bird receiving 
vaccination.  
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 Even though vaccines have been available for a number of years, they have not 
been widely accepted in terms of use when compared to anticoccidial drug usage.  
Broilers receiving a vaccine have not always performed, with regards to weight gain and 
feed conversion, as well as broilers receiving prophylactic medication (Danforth, 1998). 
Coccidiosis vaccines have been shown to reduce performance parameters early on 
followed by a period of compensatory growth during the last half of the trial after 
protective immunity has been established (Danforth et al., 1997a; Mathis, 1999).  The 
period of early performance loss is associated with the mild infection brought on by 
vaccination in order to stimulate immunity (Danforth et al., 1997a).  Studies comparing 
vaccinated broiler performance to the performance of medicated broilers have shown 
varying results.  Some reports demonstrated that vaccinated broilers did not perform as 
well as broilers fed medicated diets (Danforth, 1998; Allen and Fetterer, 2002; Williams, 
2002), while others suggest that vaccinated broilers can perform just as well if not better 
than broilers receiving medication (Mathis, 1999; Suo et al., 2006).  Despite these 
different reports, it has been well documented  that vaccination can generate increased 
weight gain, improved feed conversion, and reduce clinical lesions in broilers that have 
been challenged with Eimeria (Danforth, 1998, Crouch et al., 2003, Li et al., 2005).  
There is continuing research for the advancement of live vaccine use in the industry and 
vaccine efficacy must be improved to gain broader acceptance.  Many different ideas on 
improvement of vaccine efficacy are beginning to emerge as the industry seems to be 
moving away, to some degree, from anticoccidial drug use. 
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Probiotic Use in Commercial Poultry 
As the concern of drug resistance to anticoccidials and the threat of restricting 
certain drugs for use commercially begins to receive attention here in the U.S., the need 
for alternative methods of coccidiosis control is vital (Lee et al., 2007).  One alternative 
that has been explored is using various dietary and microbial supplements in feed to 
influence the host’s immune system against disease (Dalloul et al., 2003; Duffy et al., 
2005).  Probiotics are live microbial supplements that improve microbial balance within 
the intestine resulting in benefits to the host (Fuller, 1989).  These bacteria, classified as 
probiotics, typically include organisms from the genera Lactobacillus, Saccharomyces, 
Bacillus, and Streptococcus (Tannock, 2001).  The most commonly found probiotic 
strains used in the poultry industry are Bacillus and Lactobacillus species (Jin et al., 
1996; Zhang et al., 2005).  In commercial poultry, maintaining a healthy gut mucosa 
represents an essential first-step in protection against invading pathogens and dietary 
antigens (Dalloul et al., 2003).  The goal in feeding probiotics to any animal is to ensure 
that a healthy microbial population exists in the gut microflora.  Probiotics are beneficial 
to the host by creating a beneficial microflora through competitive exclusion, improving 
digestion, and by changing bacterial metabolism (Jin et al., 1997).  If a balanced 
microbial population is achieved, intestinal immunological defense mechanisms are 
allowed to achieve optimum performance resulting in a better control of intestinal 
pathogens (Pollmann et al., 2005).  Studies have shown improvement in growth 
parameters and feed conversion ratio of broilers feed diets containing probiotic 
supplements when compared to broilers not receiving probiotic supplements (Cavazzoni 
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et al., 1998; Zulkifli et al., 2000; Samli et al., 2007; Gao et al., 2008; Awad et al., 2009).  
More recent studies have demonstrated the effects of probiotic usage as an effective tool 
against various enteric diseases associated with chickens (La Ragione  et al., 2004 ; 
Koenen et al., 2004).  This benefit of feeding probiotics that may allow for improved 
resistance to enteric pathogens might be related to the demonstrated ability of probiotics 
to stimulate immunity.  Farnell and colleagues (2006) reported innate immune response 
stimulation for broilers administered probiotics through stimulation of heterophil 
oxidative burst and degranulation.  Another study revealed broilers fed Lactobacillus 
based probiotics were positively immunostimulated in the presence of a field strain E. 
acervulina infection when higher levels of IFNγ and IL-2 were observed in broilers 
receiving probiotics (Dalloul et al., 2005).  These reports suggest that broilers receiving 
probiotics will potentially have an enhanced immune stimulation. Broilers are reared to a 
young age ranging from six to nine weeks in duration.  As such, there typically is 
insufficient time to develop an extremely effective immune response to many 
classifications of pathogens.  Through early immunostimulation, feeding probiotics to 
broilers could be an alternative method of enhancing the host resistance to enteric 
pathogens by creating a more responsive and developed immune system (Dalloul et al., 
2003).  The only potential negative to feeding probiotics is the possibility of over 
stimulation of the immune system, which can have a negative effect on performance 
parameters such as feed conversion and body weight gain.  To our knowledge, there has 
not been a study to date evaluating the effects of probiotic administration on broilers 
receiving a non-attenuated, live oocyst coccidiosis vaccine.  If probiotics stimulate early 
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immunity in broilers, a reduction in the well documented early production losses 
associated with the low-level infection introduced by the vaccine might be achievable.  
Probiotics and other natural feed additives are likely going to be integrally involved in 
the future with regard to natural supplementation programs for control of diseases and 
maintenance of a healthy digestive tract in commercial poultry.  
 
Conclusion 
Coccidiosis will continue to be a concern in both the world and the U.S. poultry 
industry.  The purpose of the current research project was to evaluate the effects of a 
commercially available probiotic on live oocyst coccidiosis vaccinate efficacy in 
broilers.  Experiments were conducted measuring performance parameters and intestinal 
health parameters of broilers administered probiotics and a non-attenuated live oocyst 
vaccine, as well as a combination of the two.  The working hypothesis was that by 
stimulating mucosal immunity through probiotic administration, while simultaneously 
vaccinating to build immunity against Eimeria, allowance for an improvement in 
vaccine efficacy throughout the course of broiler grow-out would be achievable.   
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CHAPTER III 
BROILER PERFORMANCE DURING LIVE OOCYST 
COCCIDIOSIS VACCINATION: INFLUENCE OF PROBIOTIC 
ADMINISTRATION 
 
Introduction 
Coccidiosis is an enteric disease that the poultry industry has battled ever since 
the beginning of commercial poultry production.  The disease is caused by a parasitic 
protozoan of the genus Eimeria.  Several species exist that are known to parasitize the 
epithelial cells of the intestine of chickens causing moderate to severe damage to the 
intestinal lining or mucosa of the bird (Conway and McKenzie, 2007).  Subclinical and 
clinical cases of coccidiosis are responsible for severe economic and performance losses 
every year in the industry (Lee et al., 2009).  The high density rearing conditions of 
modern commercial broiler production represent an ideal environment for survival and 
propagation of Eimeria oocysts.  Historically, the primary control method for poultry 
producers to combat this disease has been prophylactic treatment through the use of 
anticoccidial drugs or “coccidastats”.  The most commonly used anticoccidial drugs are 
classified into two categories, synthetic anticoccidials and ionophores.  Synthetic 
anticoccidials (chemicals) are produced by chemical synthesis and affect parasite 
metabolism at some point in the reproductive life cycle.  Ionophorous antibiotics 
(ionophores) are produced by fermentation and function using a mechanism that affects 
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ion transport across the parasite membrane to disrupt osmotic balance (Chapman, 1999; 
Allen and Fetterer, 2002).  Through the years, these drugs have played a significant role 
in the success of the industry by suppressing the negative influence of Eimeria infection 
on broiler performance (Allen and Fetterer, 2002).  One concern that has burdened the 
industry ever since the introduction of anticoccidial drugs is the development of drug 
resistance to anticoccidials resulting from continued use.  Extensive use of anticoccidial 
drugs, including the ionophores, has generated resistance among Eimeria species 
through reduction of sensitivity to these drugs in the field (McDougald, 1981).  Many 
studies have shown resistance is emerging in the field to all types of anticoccidials 
currently being used (Jeffers, 1974; Chapman, 1986; McDougald, 1990; Williams, 2006; 
Bafundo et al., 2008).  Alternative methods must be considered in order to assure 
continued control of this disease.  
At present, the only viable and proven alternative approach to controlling 
coccidiosis in commercial poultry involves immunological stimulation, which can 
provide for long term protective immunity to subsequent Eimeria infection (Williams, 
1994).  Vaccines have been available for use by the industry for coccidiosis control for 
many decades, with most common usage being in replacement breeder or layer flocks 
(Williams et al., 2000).  The most common types of vaccines currently available are live 
oocyst vaccines which are either attenuated or non-attenuated.  Non-attenuated vaccines 
have been shown to be successful in stimulating long term protective immunity in 
poultry (Shirley and Millard, 1986; Long et al., 1986; Bedrnik et al, 1989; Shirley, 
1989).  They are not always widely accepted by broiler integrators since the Eimeria 
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present in the vaccine are more virulent than oocysts found in attenuated vaccines, and 
often are associated with some degree of performance loss (Danforth et al., 1997b; 
Mathis, 1999; Chapman, 2002).  Since these non-attenuated oocysts are unaltered 
compared to attenuated vaccines, they likely provide for a more natural immune 
response increasing magnitude and longevity of protective immunity (Lillehoj and 
Lillehoj, 2000).  Attenuation of oocysts is also associated with high production costs for 
a low yield of product, making this type of vaccine more costly to the grower (Dalloul 
and Lillehoj, 2005).  Attenuated and non-attenuated vaccines have both been successful 
with regard to stimulating protective immunity to coccidiosis (Shirley and Millard, 1986; 
Long et al., 1986; Bedrnik et al, 1989; Shirley, 1989).  Broiler performance during 
vaccination, however, when compared to birds receiving prophylactic anticocidials in 
the diet, has not been always been positive (Danforth, 1998).  The current shift in 
consumer preference regarding poultry rearing in a direction away from traditional 
medicated control strategies suggests that vaccination should continue to become more 
of a primary method of coccidiosis control in future years.  For vaccines to become a 
more relied upon control measure for traditional integrated broiler production, several 
inconsistencies associated with efficacy and administration require improvement.  
Probiotic bacteria have been suggested by several investigators to be a natural 
control method for coccidiosis (Dalloul et al., 2003; Duffy et al., 2005).  The commensal 
bacteria present in probiotic cultures colonize epithelial surfaces of the gut in the 
intestinal tract of the host (Fuller, 1989).  When introduced to the host, probiotics assist 
in the development of a beneficial microflora through competitive exclusion, which in 
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turn improves digestion and changes bacterial metabolism (Jin et al., 1997).  This 
colonization has been shown to stimulate mucosal immunity during times of enteric 
pathogen invasion, thereby increasing the host’s resistance to the invading pathogen 
(Dalloul et al., 2003).  Intestinal pathogens can then be detected and destroyed by the 
host immune system more effectively because a balanced and healthy microbial 
population could allow for the intestinal immunological defense mechanisms to achieve 
optimum performance, resulting in a more functional and timely immune system 
(Pollmann et al., 2005).  The objective of this investigation was to determine if the 
drinking water administration of the commercially available probiotic for poultry, 
Biomin PoultryStar®, would improve broiler performance and efficacy of the live oocyst 
coccidiosis vaccine, Coccivac-B®, during a 48 day pen trial.  We hypothesize that 
administration of probiotic during live coccidiosis vaccination will improve broiler 
performance and vaccine efficacy during this simulated commercial grow-out.       
 
Materials and Methods 
Experimental Design 
This experimental trial was conducted in a broiler rearing barn at the Texas 
A&M University Poultry Science Teaching, Research, and Extension Center in College 
Station, TX.  Animal care and husbandry were provided in accordance with an approved 
Texas A&M Institutional Animal Care and Use (IACUC) protocol.  The experimental 
design was a 2X2 factorial (vaccine and probiotic) based ANOVA design with four 
experimental groups.  Groups evaluated were control, probiotic alone, vaccine alone, and 
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combination of probiotic and vaccine (Vaccine + Probiotic).  Each experimental group 
had 10 replicate pens randomly distributed throughout the barn bringing the total number 
of pens to 40.  Experimental parameters evaluated included body weight, mortality 
corrected feed conversion, and oocyst output (oocysts shed per gram (OPG) of feces).  
Body Weight and Feed Conversion Ratio (FCR) 
Body weights were determined on day of placement (d zero), on the day of each 
feed change (d 15, 30, 40), and again at termination (d 48).  Body weights were collected 
as bulk pen weights and the number of animals present in each pen at the time of 
weighing allowed for calculation of average broiler weight within each pen.  Mortality 
corrected feed conversion ratio (FCR) was calculated on d 15, 30, 40, and 48.   
Oocyst Output (OPG Determination) 
Feces were collected from four pens per experimental group beginning on d six 
post-placement and continuing on an every other day basis until termination of the trial 
for calculation of oocyst output per gram of feces.  After collection of the feces, five 
grams of fecal material from each sample collected was weighed and diluted in 15 ml of 
water.  Samples were then homogenized and an appropriate volume was loaded onto a 
McMasters counting chamber using a 200 ul pipette.  Using a standard light microscope 
and a 20X objective, non-sporulated oocysts were counted to determine the oocyst 
output per gram of feces (OPG).  
Experimental Animals and Rearing 
The experimental animals used in this trial were straight-run Cobb x Ross 
broilers obtained at day of hatch from a local commercial hatchery on day-of-hatch.  
 
 
35 
 
 
Each chick was weighed and received a wing-band for identification prior to placement 
in rearing pens.  To ensure uniform body weights at placement (d 0) for all experimental 
rearing pens or groups, all chicks were randomized according to d 0 body weight.  This 
was performed by separating the heaviest and the lightest 5 % of all d zero body weights 
and then randomly distributing the remaining chicks to allow for an evenly distributed 
starting pen weight for each pen.  Broilers were distributed to rearing pens at placement 
density of 0.8 ft2 per bird to simulate local commercial broiler rearing conditions.  This 
required 45 chicks to be placed per pen achieving a total placement of 1,800 straight-run 
broilers for the entire trial.  Each pen contained a 30 pound tube feeder and commercial-
style nipple drinkers.  Food and water were provided ad libitum to all broilers throughout 
the trial.  The litter or bedding material within each pen during this trial was comprised 
of 50% fresh pine shavings and 50% used litter removed from a local commercial broiler 
rearing barn.  Birds were fed a non-medicated, corn-soy based diet formulated to 
approximate the diets of a local broiler integrator.  Diets were fed to broilers during this 
trial according to a four-phase program.  This called for the feeding of a crumbled starter 
diet (d one to 15), followed by pelleted grower (d 15 to 30), pelleted finisher (d 30 to 
40), and pelleted withdrawal (d 40 to 48) diets. 
Vaccination and Probiotic Administration 
 Birds designated for vaccination were spray vaccinated using a commercial style 
(Spraycox® II) vaccination cabinet.  The vaccine used was Coccivac®-B 
(Intervet/Schering-Plough Animal Health, Millsboro, DE), a non-attenuated 
commercially available live oocyst coccidiosis vaccine for broiler chickens.  After 
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vaccination, chicks were allowed to preen for at least one hour before placement in 
rearing pens.  Probiotic was administered intermittently through the drinking water using 
a commercial-style water medication system present in the rearing barn.  The probiotic 
administered was Biomin® Poultry Star (Biomin GmbH, Herzogenburg, Austria), a 
commercially available viable probiotic culture containing beneficial bacterial 
microflora, including Enterococcus faecium, Pediococcus acidilactici, Bifidobacterium 
animalis, and Lactobacillus reuteri, in addition to the carrier inulin.  Probiotic was 
applied at a concentration 20 g per 1000 broilers according to manufacturer’s dosage 
recommendations.  Broilers designated for probiotic administration received intermittent 
drinking water application on d zero through four, d eight through ten, and then again 
one day prior through one day following feed change (d 14 through 16, 29 through 31, 
and 39 through 41).  Probiotic containing drinking water was colored with a red and 
green food coloring dye in a pattern that alternated colors on consecutive days.  The 
presence of a dye in the drinking water allowed water lines to be completely drained and 
re-filled each day of probiotic administration.   
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Statistical Analysis 
Data were analyzed using a factorial ANOVA for vaccine and probiotic 
administration in the GLM Procedure (SPSS v 11.0).  Means were deemed statistically 
different at P ≤ 0.05.  A significant interaction was present with regard to body weight 
on d 40.  Thus, these data were subjected to a one-way ANOVA.  Means were separated 
using a Duncan’s Multiple Range test.  Mortality was subjected to an arcsine 
transformation prior to analysis. 
 
Results 
Experimental parameters investigated during this trial included body weight, 
mortality corrected feed conversion ratio (FCR), cumulative mortality, and oocyst output 
or shedding measurements (oocyst shed per gram (OPG) of feces).  Vaccinated broilers 
were observed to have a significant (P<0.05) reduction in body weight on d 30 of grow-
out compared to non-vaccinated broilers (Table 3-1).  
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Table 3-1. Average body weights (kg) for broilers in all experimental groups on the day of each feed change and termination 
of the trial. 
Day 15 Day 30 
 Control Probiotic Mean  Control Probiotic Mean 
Non-Vacc 0.52 ± 0.00 0.51 ± 0.01 0.51 ± 0.00 Non-Vacc 1.73 ± 0.02 1.70 ± 0.01 1.71 ± 0.01a 
Vacc 0.52 ± 0.01 0.52 ± 0.00 0.52 ± 0.00 Vacc 1.64 ± 0.01 1.66 ± 0.02 1.65 ± 0.01b 
Mean 0.52 ± 0.00 0.51± 0.00  Mean 1.68 ± 0.02 1.68 ± 0.01  
Day 40* Day 48 
 Control Probiotic Mean  Control Probiotic Mean 
Non-Vacc 2.55 ± 0.02a 2.51 ± 0.01ab 2.53 ± 0.01 Non-Vacc 3.18 ± 0.02 3.08 ± 0.02 3.13 ± 0.02 
Vacc 2.45 ± 0.03b 2.50 ± 0.03ab 2.48 ± 0.02 Vacc 3.10 ± 0.04 3.13 ± 0.04 3.12 ± 0.03 
Mean 2.50 ± 0.02 2.50 ± 0.01   Mean 3.14 ± 0.02 3.11 ± 0.02  
  a,b Means of main effects on different sampling days with different subscripts differ significantly at P<0.05. 
*a,b Means of individual experimental groups with different subscripts differ significantly at P<0.05 due to a significant    
      interaction observed between vaccine and probiotic.
39 
 
 
At termination of the trial on d 48, however, differences in body weight among 
broilers in all experimental groups were not observed.  A probiotic associated interaction 
(P<0.05) was observed among vaccinated broilers with respect to body weights on d 48 
(Table 3-1).   
A significant (P<0.05) increase in FCR in vaccinated broilers was noted during 
the grower (d 15 to 30) phase of grow-out, similar to observed trends of reduced body 
weight (Table 3-2).  Improvements (P<0.05) in FCR were observed in vaccinated  
broilers during the withdrawal (d 40 to 48) phase of this trial, suggesting improved 
performance and efficiency during the later phases of grow-out.  Probiotic 
administration did not effect FCR  during any of the dietary phases of this trial (Table 3-
2).  Differences among broilers in all experimental groups were not observed at 
termination of the trial for cumulative FCR (Table 3-2).  Cumulative mortality was 
significantly (P<0.05) reduced in broilers receiving probiotic (Table 3-3). 
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Table 3-2. Average mortality corrected feed conversion ratio (FCR) of all experimental groups during each dietary phase and 
at termination of the trial. 
Starter (FCR) Grower (FCR) 
 Control Probiotic Mean  Control Probiotic Mean 
Non-Vacc 1.17 ± 0.01 1.20 ± 0.02 1.19 ± 0.01 Non-Vacc 1.58 ± 0.02 1.57 ± 0.01 1.57 ± 0.01b 
Vacc 1.16 ± 0.01 1.17 ± 0.01 1.17 ± 0.01 Vacc 1.66 ± 0.01 1.66 ± 0.02 1.66 ± 0.01a 
Mean 1.17 ± 0.01 1.19 ± 0.01  Mean 1.62 ± 0.02 1.62 ± 0.02  
Finisher (FCR) Withdrawal (FCR) 
 Control Probiotic Mean  Control Probiotic Mean 
Non-Vacc 2.27 ± 0.02 2.25 ± 0.02 2.26 ± 0.01 Non-Vacc 2.59 ± 0.04 2.83 ± 0.10 2.72 ± 0.06a 
Vacc 2.28 ± 0.04 2.25 ± 0.02 2.26 ± 0.02 Vacc 2.53 ± 0.05 2.50 ± 0.06 2.52 ± 0.04b 
Mean 2.28 ± 0.02 2.25 ± 0.01   Mean 2.56 ± 0.03 2.67 ± 0.07  
Cumulative (FCR) Day 1-48     
 Control Probiotic Mean     
Non-Vacc 1.92 ± 0.01 1.95 ± 0.01 1.93 ± 0.01     
Vacc 1.96 ± 0.02 1.96 ± 0.02 1.96 ± 0.01     
Mean 1.94 ± 0.01 1.95 ± 0.01      
 a,b  Means of main effects during different sampling phases with different subscripts differ significantly at P<0.05. 
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Table 3-3. Cumulative mortality of broilers from each experimental group throughout 
the entire trial. 
Average Mortality % 
 Control Probiotic Mean 
Non-Vacc 4.09 ± 0.76 2.27 ± 0.97 3.18 ± 0.56b 
Vacc 7.95 ± 1.30 4.08 ± 2.00 6.02 ± 1.02a 
Mean 6.02 ± 0.88a 3.18 ± 0.76b  
a,b Means of main effects with different subscripts differ significantly at P<0.05. 
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Oocyst output data supported the body weight and mortality corrected feed 
conversion ratio data that was measured in this trial.  Vaccinated broilers had an increase 
in oocyst output during the first 26 days of the trial, which can be related to the reduction 
in body weight on day 30 and an increase in mortality corrected feed conversion ratio 
observed for vaccinated broilers during the grower (d 15 to 30) phase of rearing.  After 
day 26 vaccinated broilers oocyst output diminished to virtually nothing which allowed 
for improved performance parameters during the final weeks of the trial.  Non-
vaccinated broilers showed an increase in oocyst output after d 26, which corresponds to 
the observed slight performance loss, which could be associated with mild infection, that 
allowed for vaccinated broilers to compensate for the earlier performance losses that 
these broilers experienced (Figure 3-1).  
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Figure 3-1. Oocyst output (oocyst per gram (OPG) of feces) from four randomly selected pens 
from each experimental group beginning on d six and continuing on an every other day basis 
until d 40. 
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Discussion 
When a broiler receives a live oocyst coccidiosis vaccine, it is not uncommon to 
experience some degree of performance loss in the early phases of production due to the 
mild infection brought on by vaccination (Chapman et al., 2002).  In order to stimulate 
protective immunity during later phases of rearing, exposure to the parasite must occur 
early in the animal’s life.  Body weights and FCR were negatively affected by 
vaccination during the grower phase of the current trial (Table 3-1, 3-2).  Body weights 
on d 30 for vaccinated broilers were lower than non-vaccinated broilers, representing a 
performance loss during the period of vaccine-induced infection.  Similarly, FCR in the 
grower phase reflected this pattern among vaccinated birds with a significant increase in 
FCR when compared to non-vaccinated broilers during period of grow-out (Table 3-2).  
These findings were expected and are supported by previously published work that 
yielded similar findings (Danforth et al., 1997a; Mathis, 1999).  This observation 
suggests that the probiotic administration improved vaccine efficacy throughout the 
withdrawal phase of the trial.   
During commercial grow-out, broilers are exposed to and can be infected by field 
strain Eimeria present in the rearing environment.  Throughout this trial OPG data was 
collected in order to determine the presence of wild type and vaccine strain Eimeria that 
existed in rearing environment of this pen study.  Oocyst output was reduced after d 26 
of the trial for vaccinated broilers (Figure 3-1).  Although body weights were not 
significantly different at termination, the pattern of oocyst output for vaccinated broilers 
can be associated with a decrease of FCR during the withdrawal phase of this trial.  
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Mortality was recorded daily during the duration of the trial and birds receiving probiotic 
had a reduction in cumulative mortality at termination of the trial.  To our knowledge, 
these or similar observations have not been reported in literature.   
Earlier research has been reported which suggests vaccination decreased 
cumulative mortality (Danforth, 1998), however in this trial, our observations revealed 
that vaccination did not significantly (P<0.05) reduce cumulative mortality.  Non-
vaccinated broilers showed an increase in oocyst output after d 26 of this trial (Figure 3-
1).  However, output was still considerably lower during this time then the peaks seen 
early on associated with vaccinated broilers.  Birds were raised on used litter, but oocyst 
output data suggest that, though Eimeria was present in the litter, the concentration of 
field-strain oocysts was likely not enough to induce a significant infection in non-
vaccinated broilers.  Mild infection during the last 14 to16 days of the trial in non-
vaccinated broilers could be associated with the vaccinated birds gaining more weight in 
the final phases of the trial allowing these birds to complete the trial with similar 
performance numbers.  Taken together, these observations suggest that the 
administration of a probiotic in combination with a live oocyst vaccine may lead to 
improved performance during coccidiosis vaccination in broilers, potentially due to 
enhanced immunostimulation and vaccine efficacy that positively affect enteric health 
during rearing.   
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CHAPTER IV 
EVALUATION OF PROBIOTIC ADMINISTRATION ON 
COCCIDIOSIS VACCINATION IN BROILERS:  EFFECTS ON 
PERFORMANCE PARAMETERS AND OOCYST OUTPUT 
 
Introduction 
Avian coccidiosis, caused by the protozoan pathogen of the genus Eimeria, is 
one of the most economically important health problems within the commercial poultry 
industry.  Eight species of Eimeria are known to parasitize the intestinal epithelium of 
the chicken, causing pathophysiological complications that include morbidity, watery or 
mucoidal diarrhea, and even hemorrhagic diarrhea or death (Kogut, 1990).  Concerns 
over drug resistance associated with the continuous feeding of anticoccidial drugs in 
poultry diets have existed since the industry began using anticoccidials as a primary 
control method for avian coccidiosis decades ago (McDougald, 1981).  More recently, 
the industry has shown a keen interest in developing alternative methods for controlling 
coccidiosis in commercial poultry flocks.  Alternative methods that have been 
researched to date include live oocyst vaccination and drug-free additives such as 
probiotics or direct fed microbial cultures.  
Vaccination has been available for use in the industry for approximately 60 or 
more years (Edgar, 1958; Shirley and Bellatti, 1988).  There are two types of vaccines 
commonly used in the industry, attenuated and non-attenuated live oocyst vaccines.  
Attenuated vaccines have been more appealing to growers in the past because they are 
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less virulent then their non-attenuated counterparts (Williams, 1994).  Non-attenuated 
vaccines have been proven affective and may have advantages in stimulating protective 
immunity over attenuated vaccines (Lillehoj and Lillehoj, 2000).  Non-attenuated live 
oocyst vaccines likely provide added protection, when compared to attenuated vaccines, 
during subsequent Eimeria challenge since they are unaltered oocysts that are more 
similar to field strains encountered by poultry during commercial grow-out.  Both types 
of vaccines have been shown to stimulate some degree of long term protective immunity 
to coccidiosis (Shirley and Millard, 1986; Long et al., 1986; Bedrnik et al, 1989; Shirley, 
1989; Allen et al., 1997).  There are concerns, however, regarding the efficacy of 
vaccines in the minds of many producers and tech service personnel, as many feel 
anticoccidials have been shown to be more effective under field applications.  As such, 
additional research into vaccine efficacy and usage is needed. 
Another alternative method of control that has been explored recently involves 
the use of microbial feed additives, probiotics or direct fed microbials, which have 
potential properties of stimulating mucosal immunity in poultry.  Probiotics are naturally 
occurring live strains of bacteria that can be beneficial to the host gut microflora either in 
terms of intestinal development, nutrient utilization, or defense against enteric pathogen 
challenge (Tannock, 2001; Dalloul et al., 2003; Duffy et al., 2005).  The inclusion of 
probiotics in feed has been shown to stimulate mucosal immunity and perhaps aid in the 
host defense against invading pathogens (La Ragione et al., 2004; Koenen et al., 2004).  
To date, very little research, if any, has focused upon the effects of probiotic 
administration on coccidiosis vaccination in commercial poultry.  Given the effects 
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observed to date, which suggest probiotics improve gut maturation, nutrient utilization, 
and intestinal immunity in commercial poultry, we feel investigation into the potential 
positive effects probiotics may have on enteric vaccination, including coccidiosis 
vaccination in commercial strain poultry, is warranted.  The purpose of the following 
research was to evaluate coccidiosis vaccination (Coccivac®-B), with or without 
drinking water probiotic (Biomin® PoultryStar) administration, in commercial strain 
broiler chickens for protection against field strain Eimeria challenge during a 42 day pen 
trial.  Our hypothesis was that feeding probiotics to broilers during live coccidiosis 
vaccination could improve vaccine efficacy and resultantly improve protection against 
field-strain Eimeria challenge during a 42 day pen trial.  
 
Materials and Methods 
Experimental Design 
This experimental trial was conducted in a broiler rearing barn at the Texas 
A&M University Poultry Science Teaching, Research, and Extension Center facility in 
College Station, TX.  Animal care and husbandry were provided in accordance with an 
approved Texas A&M Institutional Animal Care and Use (IACUC) protocol.  The 
experimental design was a 2X2 factorial (vaccine and probiotic) based ANOVA design 
with four experimental groups.  Groups evaluated were control, probiotic alone, vaccine 
alone, and combination of probiotic and vaccine (Vacc + Prob).  Each experimental 
group had 10 replicate pens randomly distributed throughout the barn bringing the total 
number of pens to 40.  Birds were reared to day 42 under industry simulated rearing 
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conditions.  A field strain Eimeria challenge was spray applied to the litter for all pens in 
the study on d 14 of the trial.  On d 35, four birds from each pen were removed, 
weighed, and challenged by oral gavage before being placed in four separate pens 
according to respective experimental group.  These birds were reared for the last seven 
days of the trial in these pens to evaluate performance and intestinal parameters during a 
clinical challenge.  Experimental parameters measured for all birds in the main 
performance trial included body weight, mortality corrected feed conversion (FCR), and 
oocyst output associated with vaccination or challenge (oocysts shed per gram (OPG) of 
feces).  Intestinal and performance parameters for the clinically challenged birds 
included gross and microscopic intestinal lesion score, intestinal weights, and weight 
gain over the seven day challenge period.   
Body Weight and Feed Conversion Ratio (FCR) 
Body weights were determined on day of placement (d zero), on the day of each 
feed change (d 14, 28, 35), and again at termination (d 42).  Body weights were collected 
as bulk pen weights and the number of animals present in each pen at the time of 
weighing allowed for calculation of average broiler weight within each pen.  Mortality 
corrected feed conversion ratio (FCR) was calculated on d 14, 28, 35, and 42.   
Oocyst Output (OPG Determination) 
Feces were collected from four randomly selected  pens per experimental group 
beginning on d six post-placement and continuing on an every other day basis until 
termination of the trial for calculation of oocyst output per gram of feces.  After 
collection of the feces, five grams of fecal material from each sample collected was 
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weighed and diluted in 15 ml of water.  Samples were then homogenized and an 
appropriate volume was loaded onto a McMasters counting chamber using a 200 ul 
pipette.  Using a standard light microscope and a 20X objective, non-sporulated oocysts 
were counted to determine oocyst output per gram of feces (OPG).  
Experimental Animals and Rearing 
The experimental animals used in this trial were straight-run Cobb x Ross 
broilers obtained on day-of- hatch from a local commercial hatchery.  Each chick was 
weighed and received a wing-band for identification prior to placement in rearing pens.  
To ensure uniform body weights at placement for all experimental rearing pens or 
groups, all chicks were randomized according to day-of-hatch body weight.  This was 
performed by separating the heaviest and the lightest 5 % of all d zero body weights and 
then randomly distributing the remaining chicks to allow for an evenly distributed 
starting pen weight for each pen.  Broilers were distributed to rearing pens at placement 
density of 0.8 ft2 per bird to simulate local commercial broiler rearing conditions.  This 
required 45 chicks to be placed per pen achieving a total placement of 1,800 straight-run 
broilers for the entire trial.  Each pen contained a 30 pound tube feeder and commercial-
style nipple drinkers.  Food and water were provided ad libitum to all broilers throughout 
the trial.  The litter or bedding material within each pen during this trial was comprised 
of litter used to rear broilers in a previous trial (Chapter III), top dressed with an 
equivalent amount per pen of fresh pine shavings.  Birds were fed a non-medicated, 
corn-soy based diet formulated to approximate the diets of a local broiler integrator.  
Diets were fed to broilers during this trial according to a four-phase program.  This 
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called for the feeding of a crumbled starter diet (d zero to 14), followed by pelleted 
grower (d 14 to 28), pelleted finisher (d 28 to 35), and pelleted withdrawal (d 35 to 42) 
diets. 
Vaccination and Probiotic Administration 
 Birds designated for vaccination were spray vaccinated using a commercial style 
(Spraycox® II) vaccination cabinet.  The vaccine used was Coccivac®-B 
(Intervet/Schering-Plough Animal Health, Millsboro, DE), a non-attenuated 
commercially available live oocyst coccidiosis vaccine for broiler chickens.  After 
vaccination, chicks were allowed to preen for at least one hour before placement in 
rearing pens.  Probiotic was administered intermittently through the drinking water using 
a commercial-style water medication system present in the rearing barn.  The probiotic 
administered was Biomin® Poultry Star (Biomin GmbH, Herzogenburg, Austria), a 
commercially available probiotic culture containing beneficial bacterial microflora, 
including Enterococcus faecium, Pediococcus acidilactici, Bifidobacterium animalis, 
and Lactobacillus reuteri in addition to  the carrier inulin.  Probiotic was applied at a 
concentration 20 g per 1000 broilers according to manufacturer’s dosage 
recommendations.  Broilers designated for probiotic administration received intermittent 
drinking water application on d zero through three, d eight to ten, and then again one day 
prior through one day following feed change (d 13 through 15, 27 through 29, and 34 
through 36).  Probiotic containing drinking water was colored with a red or green food 
coloring dye in a pattern that alternated colors on consecutive days.  The presence of a 
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dye in the drinking water allowed water lines to be completely drained and re-filled each 
day of probiotic administration.   
Field Strain Eimeria Challenge 
Eimeria oocysts used for both the d 14 litter spray challenge and the d 35 oral 
challenge were field strain species derived from a local commercial broiler production 
facility.  Eimeria species in the challenge inoculum included E. acervulina, E. tenella, E. 
maxima, and E. mivati. The d 14 challenge involved spray applying 35,000 oocyst per 
bird to the litter in each rearing pen.  Broilers removed from grow-out pens that were 
orally challenged on d 35 received approximately 550,000 oocyst per bird. 
Indices of Clinical Eimeria Challenge 
Broilers designated for clinical challenge were removed on d 35 from 
performance rearing pens and placed in 4 separate pens according to experimental group. 
The body weight of each individual bird was recorded before placement in designated 
pens.  After the seven day challenge period, each broiler was weighed in order to 
calculate weight gain during challenge.  Once the weight was recorded, the bird was 
killed and necropsy was performed.  Gross upper (duodenal loop), mid (jejunum and 
ileum), and lower (cecum) intestine lesion scores were determined following methods 
published by Johnson and Reid (1970).  After gross lesion scores were determined, a 
scrapping of each intestinal section was taken and placed on a microscope slide with a 
coverslip.  Each slide was examined using a standard light microscope with a 20X 
objective to determine the upper, mid, and lower microscopic intestinal lesion score.  In 
total, 10 samples from each group were subjected to this method of lesion scoring.  The 
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final intestinal parameter measured was upper (small intestine) and lower (large 
intestine) intestinal weight.  Ingesta or fecal material was removed with water and 
physical action before intestinal sections were weighed.  
Statistical Analysis 
All data were analyzed using a factorial ANOVA for vaccine and probiotic 
administration in the GLM Procedure (SPSS v 11.0).  Means were deemed statistically 
different at P ≤ .05.  A significant interaction was present with regard to mid gross and 
microscopic lower-intestinal lesion score.  Thus, data were subjected to a one-way 
ANOVA.  Means were separated using a Duncan’s Multiple Range test.   
 
Results 
 At termination of this trial body weight, body weight gain, and mortality 
corrected feed conversion ratio in broilers in all experimental groups were compared.  
Average body weight was significantly (P<0.05) decreased on d 28 in vaccinated 
broilers when compared to non-vaccinated broilers.  However at termination of the trial 
on d 42, there were no significant differences in body weight among broilers in all 
experimental groups (Table 4-1).  
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Table 4-1. Average body weights (kg) for broilers in all experimental groups on the day of each feed change and termination 
of the trial on d 42. 
Day 14  Day 28 
 Control Probiotic Mean   Control Probiotic Mean 
Non-Vacc 0.44 ± 0.00 0.43 ± 0.01 0.43 ± 0.01  Non-Vacc 1.52 ± 0.01 1.53 ± 0.02 1.52 ± 0.01a 
Vacc 0.43 ± 0.01 0.44 ± 0.00 0.44 ± 0.00  Vacc 1.49 ± 0.01 1.47 ± 0.02 1.48 ± 0.01b 
Mean 0.44 ± 0.00 0.43± 0.00   Mean 1.50 ± 0.01 1.50 ± 0.01  
Day 35  Day 42 
 Control Probiotic Mean   Control Probiotic Mean 
Non-Vacc 2.21 ± 0.02 2.21 ± 0.03 2.21 ± 0.02  Non-Vacc 2.83 ± 0.02 2.85 ± 0.03 2.84 ± 0.02 
Vacc 2.21 ± 0.02 2.20 ± 0.01 2.20 ± 0.01  Vacc 2.85 ± 0.02 2.83 ± 0.02 2.84 ± 0.02 
Mean 2.21 ± 0.01 2.20 ± 0.02    Mean  2.84 ± 0.02 2.84 ± 0.02  
a,b  Means of main effects on day 28 differ significantly at P<0.05.
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Mortality corrected feed conversion (FCR) comparisons among experimental 
groups revealed a significant (P<0.05) increase among the vaccinated broilers during the 
grower phase (d 14 to 28) of the trial, which correlates to the reduction in body weight 
observed on day 28 for vaccinated broilers.  During the finisher (d 28 to 35) and 
withdrawal (d 35 to 42) phases, a significant decrease in FCR was observed in 
vaccinated broilers, indicating improved performance in the second half of grow-out in 
vaccinated groups.  Probiotic administration was associated with a significant (P<0.05) 
reduction of FCR during the withdrawal phase of the trial.  Probiotic administration did 
not affect FCR during any other dietary phase throughout the trial (Table 4-2).  
Cumulative mortality was calculated at termination of the trial for all experimental 
groups.  However there were no differences (P>0.05) among experimental groups (Table 
4-3).
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Table 4-2. Average mortality corrected feed conversion ratio (FCR) of all experimental groups by dietary phase and at 
termination of the trial.  
Starter (FCR) Grower (FCR) 
 Control Probiotic Mean  Control Probiotic Mean 
Non-Vacc 1.18 ± 0.01 1.21 ± 0.02 1.19 ± 0.01 Non-Vacc 1.57 ± 0.01 1.58 ± 0.01 1.57 ± 0.01b 
Vacc 1.22 ± 0.02 1.21 ± 0.02 1.21 ± 0.01 Vacc 1.62 ± 0.02 1.63 ± 0.02 1.62 ± 0.01a 
Mean 1.20 ± 0.01 1.21 ± 0.01  Mean 1.60± 0.01 1.60 ± 0.01  
Finisher (FCR) Withdrawal (FCR) 
 Control Probiotic Mean  Control Probiotic Mean 
Non-Vacc 1.90 ± 0.02 1.94 ± 0.03 1.92 ± 0.02a Non-Vacc 2.23 ± 0.06 2.08 ± 0.04 2.16 ± 0.04a 
Vacc 1.86 ± 0.01 1.82 ± 0.04 1.84 ± 0.02b Vacc 2.05 ± 0.01 2.03 ± 0.04 2.04 ± 0.02b 
Mean 1.88 ± 0.01 1.88 ± 0.03   Mean 2.14 ± 0.04a 2.05 ± 0.03b  
Cumulative (FCR) Day 1-48     
 Control Probiotic Mean     
Non-Vacc 1.74 ± 0.01 1.72 ± 0.01 1.73 ± 0.01     
Vacc 1.72 ± 0.01 1.71 ± 0.01 1.71 ± 0.01     
Mean 1.73 ± 0.01 1.71 ± 0.01      
a,b  Means of main effects during different sampling phases with different subscripts differ significantly at P<0.05.
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Table 4-3. Cumulative mortality of broilers from each experimental group during the 
entire trial. 
Cumulative Mortality % 
 Control Probiotic Mean 
Non-Vacc 7.07 ± 0.76 3.41 ± 0.97 5.24 ± 0.73 
Vacc 5.61 ± 1.30 8.29 ± 2.00 6.95 ± 1.22 
Mean 6.34 ± 0.77 5.85 ± 1.23  
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Oocyst output supported the observed performance data in this trial.  Increased 
output peaks during the grower phase (d 14 to 28) for vaccinated broilers were 
associated with the increase in mortality corrected feed conversion ratio during this 
phase and the decrease in average body weight that was observed on d 28 of grow-out 
(Figure 4-1).  Vaccinated broilers also had a reduction of output during the last 16 days 
of the trial that correspond with the observed reduction of FCR and increase in body 
weight gain during these phases of grow-out.  Non vaccinated broilers in this trial were 
associated with an increase in oocyst output during the finisher and withdrawal phases of 
the diet, suggesting oocyst exposure later in production was associated with poorer 
performance in these animals when compared to vaccinated broilers (Figure 4-1).  The 
oocyst output data in this trial followed similar trends that were observed in the previous 
trial that is discussed in Chapter III of this thesis.   
Broilers that were removed from the original performance trial and challenged 
orally with field strain Eimeria were subject to performance and intestinal parameter 
evaluation during the challenge phase of this trial.  Gross lesion scoring revealed a 
significant (P<0.05) decrease in lesion score in vaccinated broilers in the upper, mid, and 
lower intestinal regions (Table 4-4).   
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Figure 4-1. Oocyst output (oocyst per gram (OPG) of feces) from four randomly 
selected pens from each experimental group starting on d six and continuing on an every 
other day basis until d 40.
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Table 4-4.  Gross intestinal lesion score, by region of intestine, for each experimental group of broilers included in the d 35 
clinical Eimeria challenge. 
Gross Upper Intestinal Legion Score *Gross Mid Intestinal Legion Score 
 Control Probiotic Mean  Control Probiotic Mean 
Non-Vacc 0.33 ± 0.09 0.14 ± 0.07 0.24 ± 0.06a Non-Vacc 0.93 ± 0.14a 0.34 ± 0.09b 0.64 ± 0.09 
Vacc 0.10 ± 0.06 0.07 ± 0.05 0.08 ± 0.04b Vacc 0.43 ± 0.09b 0.53 ± 0.10b 0.48 ± 0.07 
Mean 0.22 ± 0.05 0.10 ± 0.04  Mean 0.68± 0.09 0.44 ± 0.07  
Gross Lower Intestinal Legion Score  
 Control Probiotic Mean     
Non-Vacc 1.13 ± 0.17 0.90 ± 0.18 1.02 ± 0.12a     
Vacc 0.43 ± 0.09 0.53 ± 0.09 0.38 ± 0.06b     
Mean 0.78 ± 0.11 0.61 ± 0.11       
  a,b Means of main effects for different regions of the intestine with different subscripts differ significantly at P<0.05. 
*a,b Means of individual experimental groups with different subscripts differ significantly at P<0.05 due to a significant    
      interaction observed between vaccine and probiotic. 
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Probiotic administration was linked to a decrease (P<0.05) in gross lesion score 
in the mid intestinal region (Table 4-4).  Microscopic lesion scores were supportive of 
gross lesion scores, as vaccination reduced (P<0.05) upper, mid, and lower intestinal 
microscopic scores.  Probiotic administration reduced (P<0.05) microscopic lesion score 
in the lower intestine (Table 4-5).  
A significant interaction was observed between probiotic and vaccine in the gross 
mid intestinal region and the microscopic lower intestinal region, suggesting that all 
groups receiving treatment had a significant reduction in lesion development in that 
specific region of the intestine.  Body weights at the initiation and end of challenge 
(seven days post challenge) were used to calculate weight gain during challenge.  
Vaccinated broilers were associated with a significant (P<0.05) increase in body weight 
gain during the seven day challenge period when compared to weight gain of non 
vaccinated broilers.  Vaccination had an apparent effect on relative upper intestinal 
weights, but these findings were not shown to be significantly (P=0.07) different (Table 
4-6).
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Table 4-5.  Microscopic intestinal lesion score, by region of intestine, for each experimental group of broilers included in the d 
35 clinical Eimeria challenge. 
Micro Upper Intestinal Legion Score Micro Mid Intestinal Legion Score 
 Control Probiotic Mean  Control Probiotic Mean 
Non-Vacc 0.64 ± 0.15 0.44 ± 0.18 0.55 ± 0.11a Non-Vacc 0.82 ± 0.18 0.56 ± 0.18 0.70 ± 0.13a 
Vacc 0.00 ± 0.00 0.20 ± 0.13 0.10 ± 0.07b Vacc 0.30 ± 0.15 0.40 ± 0.16 0.35 ± 0.11b 
Mean 0.33 ± 0.11 0.32 ± 0.11  Mean 0.57± 0.13 0.47 ± 0.12  
*Micro Lower Intestinal Legion Score  
 Control Probiotic Mean     
Non-Vacc 2.00 ± 0.38a 1.10 ± 0.11b 1.60 ± 0.23     
Vacc 0.60 ± 0.31b 1.00 ± 0.26b 0.80 ± 0.20     
Mean 1.33 ± 0.29 1.05 ± 0.14      
  a,b Means of main effects different regions of the intestine with different subscripts differ significantly at P<0.05. 
*a,b Means of individual experimental groups with different subscripts differ significantly at P<0.05 due to a significant    
      interaction observed between vaccine and probiotic. 
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Table 4-6. Average body weight gain (g) and relative intestinal weights (g) for each experimental group of broilers included in 
the d 35 clinical Eimeria challenge. 
Avg. Body Weight Gain (g) Relative Upper Intestinal Wt. (g) 
 Control Probiotic Mean  Control Probiotic Mean 
Non-Vacc 616.2 ± 43 628 ± 19 622 ± 23 b Non-Vacc 3.14 ± .17 2.98 ± .16 3.06 ± 0.12 
Vacc 746.1 ± 35 691.7 ± 18 718.9 ± 20a Vacc 2.84 ± .10 2.89 ±  .11 2.86 ± 0.07 
Mean 681.2 ± 29 660.4 ± 14  Mean 2.98 ± 0.10 2.93 ± 0.09  
Relative Lower Intestinal Wt. (g)  
 Control Probiotic Mean     
Non-Vacc 0.47 ± .03 0.48 ± .03 0.48 ± 0.02     
Vacc 0.45 ± .02 0.41 ± .02 0.43 ± 0.02     
Mean 0.46 ± 0.02 0.45 ± 0.02      
a,b Means of main effects for average body weight gain with different subscripts differ significantly at P<0.05.
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Discussion 
 Body weight, weight gain, and mortality corrected feed conversion were affected 
by vaccination during this trial.  Reduced body weight was observed on d 28 when 
vaccinated broilers were compared to non-vaccinated broilers (Table 4-1).  Similarly, 
FCR was increased during the grower phase of the trial in vaccinated broilers, which can 
be directly linked to the reduction in body weight for the first 28 days of the trial. 
Vaccination causes a mild infection in broilers in order to stimulate long term protective 
immunity.  Clearly, this would be associated with these early losses in performance 
(Danforth et al., 1997b).  However during the final 14 days of this trial, vaccinated 
broilers showed a decrease in feed conversion when compared to non-vaccinated broilers 
(Tables 4-2).  Average body weight at termination of the trial showed no significant 
differences among experimental groups (Table 4-1).  These findings were not surprising 
as it has been previously published that vaccination will cause performance loses in 
broilers during the first half of rearing followed by a period of compensatory growth 
during the last half of grow-out (Danforth et al., 1997a; Mathis, 1999).  Probiotic 
administration was shown to decrease FCR in the withdrawal phase of the diet (Table 4-
2).  Previous studies have shown similar results with different types of probiotic 
supplements improving broiler performance parameters including FCR (Gao et al., 2008; 
Awad et al., 2009).  Oocyst output or shedding supports broiler performance data in this 
trial (Figure 4-1).  Output among vaccinated broilers was associated with two significant 
peaks of oocyst shedding.  The first peak occurred in both vaccinated groups between d 
14 and 18 and was more intense than the second peak which occurred between d 22 and 
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26 (Figure 4-1).  Following these peaks, vaccinated broilers were associated with 
essentially no oocyst output or shedding for the remainder of the trial.  This pattern is 
predictive of the increase in feed conversion, decrease in body weight, and decrease in 
body weight gain during the first 28 days of the trial.  The minimal output during the 
final 14 days of the trial supports these data showing a decrease in feed conversion and 
an increase in body weight.  Non-vaccinated broilers demonstrated a similar pattern of 
output with two major peaks or cycles of shedding (Figure 4-1).  These peaks, however, 
occurred during the last 14 days of the trial.  Although these peaks were less intense, 
reflecting a lower number of oocysts causing infection, they probably were the cause of 
the decrease in body weight, as well as an increase in feed conversion, seen in the non-
vaccinated broilers during the last 14 days of rearing.  These observations describe how 
vaccinated broilers were able to compensate for the losses experienced early, within the 
last 14 days of the trial, thus allowing ending body weights and FCR to be equivalent 
among experimental groups.   
Broilers that were removed from the performance trial and challenged with field 
strain Eimeria revealed similar trends respective to performance data.  Vaccinated 
broilers had an increase in weight gain when compared to non-vaccinated broilers during 
the seven day clinical challenge period (Table 4-6).  This can be associated with 
immunity to challenge obtained from previous exposure through vaccination.  Intestinal 
parameters were also affected by vaccination.  Gross and microscopic upper, mid, and 
lower lesion scores were reduced significantly in vaccinated broilers (Tables 4-4, 4-5).  
These results are similar to that of previously published trials where lesions were still 
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present in the vaccinated broilers, but they were not associated with clinical disease 
(Bushell et al., 1990; Bushell et al., 1992).  Probiotic administration was associated with 
a gross lesion score reduction in the mid intestinal region and a microscopic lesion score 
reduction in the lower intestinal region (Tables 4-4, 4-5).  It has been reported that 
feeding probiotics may reduce oocyst output during coccidiosis infection (Dalloul et al., 
2005).  This along with mucosal immune stimulation is suggestive of how broilers 
supplemented with probiotic were associated with a decrease in lesion development in 
these areas measured in our trial.  The results from the clinical challenge phase of this 
trial demonstrate that broilers that received vaccine and vaccine combined with probiotic 
had improved clinical intestinal and performance parameters during field strain Eimeria 
challenge when compared to non vaccinated broilers.  These data suggest that 
administration of a probiotic during a coccidiosis vaccination program may lead to 
improved vaccine efficacy and can potentially stimulate immunity and improve 
intestinal health in broilers receiving clinical field strain Eimeria challenge. 
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CHAPTER V 
EFFECTS OF PROBIOTIC ADMINISTRATION DURING 
COCCIDIOSIS VACCINATION ON PERFORMANCE IN 
BROILERS EXPOSEDTO FIELD STRAIN EIMERIA: 
COMPARISON TO MONENSIN ADMINISTRATION 
 
Introduction 
Every year the poultry industry experiences losses in excess of 800 million 
dollars due to the enteric disease avian coccidiosis (Allen and Fetterer, 2002).  The bulk 
of these losses exist in the form of costs of control measures and performance losses in 
infected birds.  Coccidiosis is an enteric disease of commercial poultry caused by host-
specific intracellular parasitic protozoa of the genus Eimeria.  There are eight species 
known to infect chickens, including E. acervulina, E. brunetti, E. mivati, E. maxima, E. 
mitis, E. necatrix, E. praecox, and E. tenella (Conway and McKenzie, 2007).  Clinical 
signs of infection include mucoid or watery diarrhea, hemorrhagic diarrhea, reduction in 
body weight or weight gain, high morbidity, and sudden death (Kawahara et al., 2008).  
For the past 60 years growers have relied heavily on anticoccidial drugs, such as the 
ionophore monensin, for control of coccidiosis (Chapman, 1999).  Environmental 
conditions of high density commercial rearing barns make commercial poultry houses 
ideal locations for the survival and propagation of Eimeria oocysts, the infective stage of 
this protozoan.  As such, eradication from commercial rearing operations is virtually 
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impossible.  While anticoccidial drugs have played a principal role in the degree of 
success experienced by the commercial poultry industry, this form of control is not 
without inherent problems due to constant emergence of drug resistance in field-strain 
Eimeria (Williams, 2006).  It has been well documented that some degree of resistance 
exists for all available anticoccidial drugs currently used in the U.S. (Jeffers, 1974; 
Chapman, 1986; McDougald, 1990; Williams, 2006; Bafundo et al., 2008).  This 
continuous development of resistance by field-strain coccidia has created interest in the 
search for alternative measures of control (Guzman et al., 2003). 
 Another widely researched method of control that has been around for many 
years is live oocyst coccidiosis vaccination.  Live oocyst vaccines in general fall into one 
of two categories, attenuated or non-attenuated.  Currently, vaccination with a live 
oocyst vaccine has been proposed to be the only viable alternative to anticoccidial usage 
in coccidiosis control programs (Danforth, 1998).  Current vaccines have been shown to 
stimulate immunity, but concerns related to efficacy and administration of the vaccine 
must be alleviated before vaccination receives broad-scale acceptance as a primary 
method of control (Gilbert et al., 1988; Augustine et al., 1991; Stiff and Bufando, 1993; 
Lillehoj and Trout, 1994; Williams, 1998).   
A new concept that has emerged through recent years in poultry production is the 
use of probiotic bacteria to nonspecifically stimulate the mucosal immune system of 
commercial poultry (Farnell et al., 2006).  Feeding probiotics to birds has been shown to 
stimulate intestinal immunity and improve enteric health in commercial lines of broilers 
(Dalloul et al., 2003).  Other studies have shown improvement in performance 
69 
 
 
parameters such as body weight and feed conversion ratio in broilers administered 
probiotics (Cavazzoni et al., 1998; Zulkifli et al., 2000; Samli et al., 2007).  Such reports 
suggest the administration of probiotics may enhance efficacy of enteric vaccines, 
particularly live oocyst coccidiosis vaccines that are often associated with early 
performance losses during commercial rearing.  The current research was conducted to 
evaluate broiler performance during coccidiosis vaccination (Coccivac®-B), with or 
without probiotic (Biomin® PoultryStar) administration during a 44 day pen study.  
Additionally, the potential interaction between vaccination and probiotic administration 
was compared during field strain Eimeria challenge.  We hypothesized that probiotic 
administration would improve vaccine efficacy in the presence of a field strain Eimeria 
challenge.  A medicated (monensin) diet was added to the experiment design for 
comparison of performance in birds fed a medicated industry type feed.   
 
Materials and Methods 
Experimental Design 
This trial was conducted in a broiler rearing barn at the Texas A&M University 
Poultry Science Teaching, Research, and Extension Center in College Station, TX.  
Animal care and husbandry were provided in accordance with an approved Texas A&M 
Institutional Animal Care and Use (IACUC) protocol.  The base experimental design 
consisted of eight different experimental groups including negative control, positive 
control (monensin medicated diet), probiotic (water applied), probiotic (feed applied), 
vaccine + probiotic (water applied), vaccine + probiotic (feed applied), probiotic 
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(medicated diet), and vaccine alone.  Birds were reared in a simulated commercial-type 
environment for a period of 44 days.  Each experimental group evaluated had eight 
replicate groups totaling to 64 pens in the trial.  A field strain Eimeria challenge was 
applied to feed in all pens on d 14.  A separate Eimeria feed challenge was administered 
to three birds per pen on d 36 of grow-out.  Birds designated for challenge were 
randomly selected from each rearing pen of the main trial, weighed, and placed in 
separate pens according to their respective experimental groups.  Rearing of challenged 
broilers occurred in these pens for seven days to evaluate the response of each group of 
broilers to clinical Eimeria challenge.  Experimental parameters measured for all birds in 
the main 44 day performance trial included body weight, mortality corrected feed 
conversion (FCR), and oocyst output or shedding associated with vaccination or 
challenge.  Intestinal and performance parameters for the clinically challenged broilers 
included gross and microscopic intestinal lesion score, intestinal weights, and weight 
gain over the seven day challenge period.   
Body Weight and Feed Conversion Ratio (FCR) 
Body weights were determined on day of placement (d zero), on the day of each 
feed change (d 14, 26, 34), and again at termination (d 44).  Body weights were obtained 
as bulk pen weights and the number of animals present in each pen at the time of 
weighing allowed for calculation of average broiler weight within each pen.  Mortality 
corrected feed conversion ratio (FCR) was calculated on d 14, 26, 34, and 44.   
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Oocyst Output (OPG Determination) 
Fresh fecal samples were collected from three pens per experimental group 
beginning on d six post-placement and continuing on an every other day basis until 
termination of the trial for calculation of oocyst output per gram of feces.  After 
collection of the feces, five grams of fecal material from each sample were weighed and 
diluted in 15 ml of water.  Samples were then homogenized and an appropriate volume 
was loaded onto a McMasters counting chamber using a 200 ul pipette.  Using a 
standard light microscope and a 20X objective, non-sporulated oocysts were counted to 
determine oocyst output per gram of feces (OPG).  
Experimental Animals and Rearing 
The experimental animals used in this trial were 2,880 Cobb by-product males 
off of the Cobb 500 line obtained on day-of-hatch from a local commercial hatchery.  
Each chick was weighed and received a wing-band for identification prior to placement 
in rearing pens.  To ensure uniform body weights at placement (d zero) for all 
experimental rearing pens or groups, all chicks were randomized according to d zero 
body weight.  This was performed by separating the heaviest and the lightest 5 % of all d 
zero body weights and then randomly distributing the remaining chicks to allow for an 
evenly distributed starting pen weight for each pen.  Broilers were distributed to rearing 
pens at placement density of 0.8 ft2 per bird to simulate local commercial broiler rearing 
conditions.  This required 45 chicks to be placed per pen of 64 total pens achieving a 
total placement of 2,880 broilers for the trial.  Each pen contained a 30 pound tube 
feeder and commercial-style nipple drinkers.  Feed and water were provided ad libitum 
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to all broilers throughout the trial.  The litter or bedding material within each pen during 
this trial was comprised of 50% fresh pine shavings and 50% used litter removed from 
another rearing facility where poultry had been housed.  Broilers in non-medicated 
groups were fed a corn-soy based diet formulated to approximate the nutrient density 
and requirements of a local broiler integrator.  Diets were fed to broilers during this trial 
according to a four-phase program.  This called for the feeding of a crumbled starter diet 
(d zero to 14), followed by pelleted grower (d 15 to 26), pelleted finisher (d 27 to 34), 
and pelleted withdrawal (d 35 to 44) diets.  Medicated diets contained the ionophore 
monensin at manufacturer’s recommended inclusion rates in all rations except the 
withdrawal ration.  Birds receiving probiotic in the feed were fed probiotic continuously 
throughout the entire trial to comply with the manufacturer’s application 
recommendations.  
Vaccination and Probiotic Administration 
 Birds designated for vaccination were spray vaccinated using a commercial style 
(Spraycox® II) vaccination cabinet.  The vaccine used was Coccivac®-B 
(Intervet/Schering-Plough Animal Health, Millsboro, DE), a non-attenuated live oocyst 
coccidiosis vaccine for broiler chickens.  After vaccination, chicks were allowed to 
preen for at least one hour before placement in rearing pens.  Probiotic was administered 
intermittently through the drinking water using a commercial-style water medication 
system present in the rearing barn.  The probiotic administered was Biomin® Poultry 
Star (Biomin GmbH, Herzogenburg, Austria), a commercially available probiotic 
containing beneficial bacterial microflora, including Enterococcus faecium, Pediococcus 
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acidilactici, Bifidobacterium animalis, and Lactobacillus reuteri in addition to the 
carrier inulin.  Probiotic was applied at a concentration 20 g per 1,000 broilers according 
to manufacturer’s dosage recommendations.  Broilers designated for probiotic 
administration received intermittent drinking water application d zero through three, 
eight to ten, and then again one day prior through one day following feed changes (d 13 
through 15, 25 through 27, and 33 through 35).  Probiotic containing drinking water was 
colored with a red or green food coloring dye in a pattern that alternated colors on 
consecutive days.  The presence of a dye in the drinking water allowed water lines to be 
completely drained and re-filled each day of probiotic administration.  Probiotic 
administration in the feed consisted of applying one pound per ton of feed-grade 
Biomin® Poultry Star according to manufacturer’s instructions.   
Field Strain Eimeria Challenge 
Eimeria oocysts used for both the d 14 and the d 36 feed challenge were field 
strain species derived from a local commercial broiler production facility.  Eimeria 
species in the challenge inoculum included E. acervulina, E. tenella, E. maxima, and E. 
mivati.  The d 14 challenge involved feed applying 55,000 oocyst per bird to the feed in 
each rearing pen.  The birds removed from the grow-out trial were similarly challenged 
in the feed on d 36 and received approximately 750,000 oocyst per bird. 
Indices of Clinical Eimeria Challenge 
  Broilers designated for clinical challenge were removed on d 36 from individual 
performance rearing pens and placed in separate challenge pens according to 
experimental group.  The placement weight of each individual bird was recorded before 
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placement in a designated pen.  After the seven day challenge period, each broiler was 
weighed in order to calculate weight gain during challenge.  Once the weight was 
recorded, each broiler was killed and a necropsy was performed.  Gross upper (duodenal 
loop), mid (jejunum and proximal ileum), and lower (cecum) intestine lesion scores were 
determined following methods published by Johnson and Reid (1970).  After the gross 
lesion scores were determined, a mucosal scrapping of each intestinal region was 
obtained and placed on a microscope slide with a coverslip.  All slides were then 
examined using a standard light microscope to determine the upper, mid, and lower 
microscopic intestinal lesion score.  In total, 10 samples from each group were subjected 
to this method of lesion scoring.  The final intestinal parameter measured was upper 
(small intestine) and lower (large intestine) intestinal weight.  Ingesta or fecal material 
was removed with water and physical action before the intestinal sections were weighed 
and recorded.  
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Statistical Analysis 
The experimental parameters from this trial were subject to a one way ANOVA 
(SPSS v 11.0).  Means were separated using a Duncan’s Multiple Range test.  Means 
were deemed statistically different at P ≤ .05. 
 
Results 
 The effects of coccidiosis vaccination with or without probiotic administration in 
male broilers were evaluated according to several common performance parameters 
during grow-out in this trial.  Body weights on d 14 were significantly (P<0.05) higher in 
broilers receiving medication, vaccine + probiotic (water), and medication + probiotic 
when compared to negative control broilers (Table 5-1).  At termination of the trial on d 
44, body weights for broilers receiving medication, vaccine + probiotic (water), and 
medication + probiotic were significantly (P<0.05) higher 
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Table 5-1.  Average body weights (kg) for broilers in all experimental groups on the day 
of each feed change and at termination of the trial on d 44. 
 
Experimental Group 
 
Average Body Weight  by Day (kg) 
 Day 14 Day 26 Day 33 Day 44 
Neg. Control 0.41± 0.003d 1.25 ± 0.01abc 1.89 ± 0.02abc 2.65 ± 0.02b 
Medicated Diet 0.45 ± 0.01ab 1.32 ± 0.01a 1.96 ± 0.02a 2.74 ± 0.03a 
Probiotic (water) 0.42 ± 0.01d 1.25 ± 0.01bc 1.86 ± 0.03bc 2.64 ± 0.02b 
Probiotic (feed) 0.43 ± 0.01cd 1.25 ± 0.01c 1.83 ± 0.03c 2.62 ± 0.02b 
Vacc + Prob (water) 0.44 ± 0.004bc 1.28 ± 0.01a 1.93 ± 0.02a 2.75 ± 0.02a 
Vacc + Prob (feed) 0.41 ± 0.01d 1.31 ± 0.01a 1.95 ± 0.02a 2.67 ± 0.03b 
Med + Prob 0.46 ± 0.01a 1.31 ± 0.01a 1.96 ± 0.02a 2.74 ± 0.02a 
Vaccine (alone) 0.41 ± 0.003d 1.28 ± 0.01ab 1.91± 0.02ab 2.62 ± 0.04b 
  a-d Means with different subscripts within columns differ significantly at P<0.05. 
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than weights obtained for broilers from all other experimental groups (Table 5-1).  With 
respect to mortality corrected feed conversion (FCR) during the starter phase (d one to 
14), broilers receiving probiotic + medication had the lowest measured FCR, but this 
value was not significantly (P<0.05) different than FCR measured in birds in the 
medication alone group.  Broilers in the vaccine + probiotic (water group), although not 
statistically (P<0.05) different from the medication alone group and statistically (P<0.05) 
higher than the probiotic + medication group, had a significantly (P<0.05) lower FCR 
then all other groups present in the experiment.  During the grower phase (d 14 to 26), 
broilers receiving vaccine + probiotic (water), probiotic alone (feed/water), medication, 
and medication + probiotic were associated with a significant (P<0.05) increase in FCR 
when compared to birds in the vaccine + probiotic (feed) group.  Throughout the finisher 
phase (d 26 to 33), broilers receiving probiotic alone (feed/water) had a significantly 
(P<0.05) higher FCR than birds that in the vaccine, vaccine + probiotic (feed/water), and 
medication + probiotic groups.  The withdrawal phase (d 33 to 44) was not associated 
with differences in FCR among all experimental groups (Table 5-2).  Cumulative FCR 
(d one to 44) followed trends seen with body weight in that broilers receiving vaccine + 
probiotic (water) had a significantly (P<0.05) lower feed conversion compared to all 
other groups except the medication alone , vaccine + probiotic (feed), and medication + 
probiotic groups (Table 5-2).  Cumulative mortality was calculated for all experimental 
groups in this trial, but no significant differences were observed (Table 5-3). 
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Table 5-2.  Average mortality corrected feed conversion ratio (FCR) for each 
experimental group by dietary phase and at termination of the trial. 
 
Experimental Group 
 
Mortality Corrected Feed Conversion Ratio (FCR) 
 Starter Grower Finisher Withdrawal Cumulative 
(d 1-44) 
Neg. Control 1.32 ± 0.02a 1.58 ± 0.01bc 1.92 ± 0.03bc 2.57 ± 0.06 1.89 ± 0.01ab
Medicated Diet 1.16 ±0 .01bc 1.61 ± 0.01ab 1.90 ±0 .04bc 2.53 ± 0.09 1.85 ± 0.02bc
Probiotic (water) 1.28 ± 0.02a 1.60 ± 0.02ab 2.01± 0.06ab 2.53 ± 0.10 1.89 ± 0.02ab
Probiotic (feed) 1.27 ±0 .02a 1.63 ± 0.01a 2.10 ±0 .06a 2.43 ± 0.07 1.90 ± 0.02a 
Vacc + Prob (water) 1.21 ± 0.01b 1.63 ± 0.01a 1.88 ± 0.02c 2.38 ± 0.04 1.83 ± 0.01c 
Vacc + Prob (feed) 1.30 ± 0.02a 1.55 ± 0.03c 1.85 ± 0.03c 2.57 ± 0.07 1.85 ± 0.01bc
Med + Prob 1.14 ± 0.01c 1.62 ± 0.01ab 1.88 ±0 .02c 2.56 ± 0.09 1.84 ± 0.02bc
Vaccine (alone) 1.31 ± 0.03a 1.59 ± 0.01abc 1.88 ± 0.04c 2.53 ± 0.11 1.88 ± 0.01ab
 a,b,c Means with different subscripts within columns differ significantly at P<0.05. 
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Table 5-3. Cumulative mortality of broilers in each experimental group throughout the 
entire trial. 
 
Experimental Group 
 
Cumulative Mortality % 
Neg. Control 3.04 ± 0.26 
Medicated Diet 3.12 ± 0.43 
Probiotic (water) 4.44 ± 0.46 
Probiotic (feed) 4.44 ± 0.46 
Vacc + Prob (water) 4.18 ± 0.61 
Vacc + Prob (feed) 3.60 ± 0.50 
Med + Prob 3.62 ± 0.38 
Vaccine (alone) 2.78 ± 0.45 
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Oocyst output data revealed two peaks before d 24 for all vaccinated broilers.  
Non-vaccinated groups were associated with a small peak in shedding or output between 
days 18 and 24, followed by a larger peak after d 24 of rearing (Figure 5-1).  These 
observations of oocyst output or shedding followed patterns similar to those measured in 
the previous two trials discussed in this thesis.  The vaccinated groups apparent early 
peaks were linked to vaccination while the non-vaccinated groups, including medicated 
broilers, showed later phase peaks in shedding, likely attributed to field strain Eimeria 
challenge.   
A subset of broilers from each experimental rearing pen of the main performance 
trial was removed and challenged on d 36 for evaluation of performance and intestinal 
parameters during clinical coccidiosis infection. 
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Figure 5-1. Oocyst output (oocyst per gram (OPG) of feces) from three randomly 
selected pens from each experimental group beginning on d six and continuing on an 
every other day basis until d 40. 
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During gross mid intestinal lesion scoring, a significant (P<0.05) reduction of 
lesion score among all experimental groups was observed when compared to the scores 
of the negative control group (Table 5-4).  Broilers in the probiotic alone (water) and the 
vaccine alone groups were associated with a significant (P<0.05) reduction in gross 
lower intestinal lesion score when compared to all other groups, with exception of 
broilers receiving vaccine + probiotic (feed) (Table 5-4).  Microscopic mid-intestinal 
lesion scoring revealed that broilers receiving a probiotic alone (feed/water), vaccine 
alone, and vaccine + probiotic (feed/water) had significantly (P<0.05) lower scores when 
compared to broilers administered medication alone.  Similar reductions were seen for 
microscopic lower lesion scores with all groups showing a significant (P<0.05) reduction 
in score when compared to medication alone (Table 5-5).   
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Table 5-4.  Gross intestinal lesion score, by region of intestine, for each experimental 
group of broilers included in the d 36 clinical Eimeria challenge. 
 
Experimental  Group 
 
Gross Lesion Score 
 Upper Mid Lower 
Neg. Control 0.08 ± .06 1.20 ± .13a 0.75 ± .12a 
Medicated Diet 0.00 ± .00 0.83 ± .15b 0.83 ± .12a 
Probiotic (water) 0.04 ± .04 0.74 ± .14bc 0.26 ± .01b 
Probiotic (feed) 0.04 ± .04 0.29 ± .01d 0.79 ± .15a 
Vacc + Prob (water) 0.08 ± .08 0.67 ± .12bcd 0.54 ± .12a 
Vacc + Prob (feed) 0.00 ± .00 0.42 ± .12cd 0.50 ± .13ab 
Med + Prob 0.00 ± .00 0.46 ± .12bcd 0.75 ± .11a 
Vaccine (alone) 0.04 ± .04 0.43 ± .12cd 0.30 ± .01b 
         a-d Means with different subscripts within columns differ significantly at P<0.05. 
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Table 5-5.  Microscopic intestinal lesion score, by region of intestine, for each 
experimental group of broilers included in the d 36 clinical Eimeria challenge. 
 
Experimental Group 
 
Microscopic Lesion Score 
 Upper Mid Lower 
Neg. Control 0.10 ± 0.10 0.40 ± 0.16ab 0.80 ± 0.25bc 
Medicated Diet 0.50 ± 0.17 0.80 ± 0.20a 1.60 ± 0.22a 
Probiotic (water) 0.10 ± 0.10 0.20 ± 0.13b 0.40 ± 0.16cd 
Probiotic (feed) 0.00 ± 0.00 0.20 ± 0.13b 0.20 ± 0.13d 
Vacc + Prob (water) 0.27 ± 0.14 0.18 ± 0.12b 0.09 ± 0.09d 
Vacc + Prob (feed) 0.11 ± 0.11 0.11 ± 0.11b 0.00 ± 0.00d 
Med + Prob 0.20 ± 0.13 0.50 ± 0.17ab 1.10 ± 0.18b 
Vaccine (alone) 0.20 ± 0.13 0.20 ± 0.13b 0.50 ± 0.17cd 
       a-d Means with different subscripts within columns differ significantly at P<0.05. 
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Furthermore, broilers receiving vaccine + probiotic (feed/water) and probiotic 
alone (feed) had a significantly (P<0.05) lower microscopic lower intestinal lesion score 
when compared to all other groups in the trial (Table 5-5).  
Body weight gain was determined during the seven day challenge period and 
results revealed that the broilers in the medication + probiotic and the vaccine alone had 
a significantly (P<0.05) lower body weight gain during challenge compared to all other 
groups included in the trial (Table 5-6).  Intestinal weights were taken for two regions 
that included upper (small intestine) and lower (large intestine and ceca) weights.  Upper 
relative weights were (P<0.05) lower for broilers receiving vaccine + probiotic (feed or 
water) and vaccine alone when compared to broilers receiving medication alone.  All 
groups were associated with a reduction (P<0.05) in relative lower intestinal weight 
when compared to broilers in the medication alone group (Table 5-6).    
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Table 5-6.  Average body weight gain (g) and relative intestinal weights (g) for each 
experimental group of broilers included in the d 36 clinical Eimeria challenge. 
 
Experimental Group 
 
Body Weight Gain (g) / Relative Intestinal Weight (g) 
 Weight Gain Relative Upper Wt. Relative Lower Wt. 
Neg. Control 644.25 ± 25a 3.16 ± 0.01ab 0.53 ± 0.01b 
Medicated Diet 613.57 ± 31a 3.20 ± 0.11a 0.61 ± 0.03a 
Probiotic (water) 568.17 ± 21a 2.93 ± 0.10abc 0.54 ± 0.02b 
Probiotic (feed) 617.50 ± 34a 2.95 ± 0.11abc 0.49 ± 0.01b 
Vacc + Prob (water) 576.02 ± 38a 2.72 ± 0.12c 0.52 ± 0.02b 
Vacc + Prob (feed) 575.12 ± 35a 2.80 ± 0.15bc 0.52 ± 0.02b 
Med + Prob 461.63 ± 35b 2.88 ± 0.12abc 0.54 ± 0.03b 
Vaccine (alone) 463.97 ± 28b 2.72 ± 0.11c 0.49 ± 0.01b 
        a,b,c Means with different subscripts within columns differ significantly at P<0.05. 
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Discussion  
 Given the ubiquitous nature of Eimeria in modern commercial broiler rearing 
environments, coccidiosis treatment and control is important to the profitability of the 
U.S. industry.  During this research trial, different combinations and permutations of 
control methods were evaluated to determine which method proved most efficacious in 
ameliorating performance losses during rearing and clinical parameters related to 
coccidial infection.  At termination of the trial on d 44, broiler body weights were higher 
in groups receiving medication, medication + probiotic, and vaccine + probiotic (water) 
(Table 5-1).  A d 14 field strain Eimeria challenge was administered to all rearing pens 
in this study to ensure that Eimeria was present in these pens in some capacity.  The 
final body weights suggest that the vaccine + probiotic (water) group performed just as 
well as broilers that were receiving the ionophore monensin continuously in the diet, 
excluding the withdrawal phase of rearing.  This was also supported by cumulative FCR 
data. Calculated FCR were significantly lower in broilers receiving vaccine + probiotic 
(feed/water) when compared to all groups except birds receiving ionophorous 
chemotherapy.  Differences between the medicated groups and the vaccine + probiotic 
groups when looking at cumulative feed conversion were not observed, however broilers 
receiving vaccine alone did not perform as well as medicated broilers (Tables 5-2).  This 
suggests that the probiotic may have improved vaccine efficacy during this trial allowing 
for equivalent performance when compared to medicated broilers.  Feeding probiotics to 
broilers has been shown to improve intestinal health and stimulate mucosal immunity in 
previously published research (Dalloul et al., 2003).  Mucosal immune system 
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stimulation by probiotics administered selectively during this trial could be responsible 
for the observed improved vaccine efficacy.  Other articles published within the past 
decade report that vaccinated broilers perform just as well if not better then medicated 
broilers during periods of Eimeria challenge, however an influence of probiotic 
administration was not evaluated (Mathis, 1999; Suo et al., 2006).  Late-phase 
performance differences between vaccinated and mediated broilers is likely due to 
infection in broilers receiving medication once the ionophore was removed from the feed 
during the withdrawal phase.  Interference with development of immunity by ionophore 
administration in this trial probably occurred, since it has been suggested that it takes as 
long as seven weeks in some cases to obtain complete immunity to some Eimeria 
species (Chapman, 1999; Chapman et al., 2004).  Performance parameters in broilers 
receiving vaccine + probiotic (water) with respect to body weight and FCR was 
equivalent if not improved compared to broilers receiving medication in the later phases 
of rearing during this trial.  Oocyst output or shedding data followed trends seen in the 
previous two trials reported in this Thesis (Chapters III and IV).  Vaccinated broilers 
were observed to have two major peaks in oocyst output prior to d 24, while non-
vaccinated broilers had two peaks in output following d 24 of rearing (Figure 5-1).  
 When evaluating clinical parameters associated with d 36 field strain Eimeria 
challenge, broilers in the vaccine (alone) and medication + probiotic groups had the 
lowest weight gain throughout the challenge period (Table 5-6).  These findings, 
referring to the vaccine (alone) group, contradicted previous findings by our lab that 
support a vaccination-associated increase in weight gain during challenge.  Gross 
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intestinal lesion scoring was associated with a reduction in mid and lower lesion 
development for broilers receiving vaccine alone, probiotic alone, and vaccine + 
probiotic (feed).  Probiotic-induced reductions in lesion score are likely associated with 
non-specific improvements in intestinal health through mucosal immune stimulation 
(Table 5-4).  Vaccine-associated lesion score reductions are attributable to the 
traditionally described generation of protective immunity.  Previous findings suggest that 
even though there were lesions present, they were not associated with clinical disease 
(Bushell et al., 1990; Bushell et al., 1992).  Microscopic lesion scores followed similar 
trends, with broilers in the vaccine alone, probiotic alone, and vaccine + probiotic groups 
achieving reductions in microscopic scores in the mid and lower intestinal regions 
compared to broilers receiving only the ionophore (Table 5-5).  These data suggest that 
co-administration of probiotic during coccidiosis vaccination results in performance 
parameters that are improved when compared to vaccination alone and indistinguishable 
from protection conferred by feeding an ionophore in the presence of field strain 
Eimeria. 
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CHAPTER VI 
CONCLUSION 
 
The modern commercial poultry industry, despite many consistent advances that 
have been achieved in general poultry health, continues to struggle with the enteric 
disease avian coccidiosis.  Advances in control of this enteric pathogen throughout the 
years have been made through research which has focused upon two primary control 
methods, anticoccidial chemotherapy and vaccination.  Broiler production is clearly the 
most susceptible sector of the industry to this type of disease due to high density rearing 
environments that exist throughout the industry.  Anticoccidial drug inclusion in rearing 
diets remains the primary method of control in integrated broiler production, but 
consumer preferences for more “drug-free” approaches coupled with the continuous 
development of drug resistance in field strain Eimeria are promoting the search for 
alternative control measures.  Vaccination has been used for decades by the industry but 
to date, the practice has received only limited acceptance in vertically integrated broiler 
production.  The research described in this thesis focused upon improving live oocyst 
coccidiosis vaccination efficacy through the use of probiotic bacteria.  The trials 
discussed in Chapters III and IV attempted to simulate industry-type conditions to test 
the effects of both vaccine and probiotics on broiler performance.  Vaccination has been 
reported to cause early-phase of production performance losses due to the low level 
infection induced by the vaccine to stimulate protective immunity.  Such losses in early-
phase production are usually followed by a period of compensatory growth during the 
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last half of grow-out (Danforth et al., 1997a; Mathis, 1999).  Results from the trials 
discussed in Chapters III and IV of this thesis report similar observations regarding the 
effects of vaccination on broiler performance.  In general, body weights and FCR were 
negatively impacted by vaccination through the grower phase of rearing in both trials.  
These losses were counteracted by compensatory gains in both body weight and FCR in 
the later phases of grow-out of these trials.  These observations were supported by 
oocyst output and shedding data in both experimental trials.  Vaccinated broilers, 
including vaccinated broilers receiving probiotic, were associated with peak output prior 
to d 26 of rearing in both trials.  Non-vaccinated broilers were associated with output or 
shedding that was greater later in grow-out, following d 26.  Greater magnitude of output 
in vaccinated broilers prior to this point in rearing corresponds to diminished 
performance through the grower phase of rearing.  A general absence of shedding or 
output after the grower phase can be linked to improved performance  in vaccinated 
animals following this time point in both trials.     
The positive impact of probiotic administration on vaccination was observed in 
several different observations of both trials from Chapters III and IV.  In the data 
reported within Chapter III, probiotic administration was observed to have a positive 
interaction with vaccination for ending broiler body weight during this trial, as the 
probiotic + vaccine group had the highest body weight at termination (P=.053).  This 
suggests an improvement in vaccine establishment and efficacy when combined with 
probiotic administration.  A positive effect of probiotic administration was also seen on 
cumulative mortality of broilers within the trial described in Chapter III.  In this trial, 
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broilers within the probiotic alone experimental group had reduced (P<0.05) cumulative 
mortality compared to all other experimental groups.  Further, broilers in the vaccine + 
probiotic group had lower (P<0.05) mortality as compared to the vaccine alone 
experimental group.  During the trial reported in Chapter IV, a positive impact of 
probiotic administration on feed conversion was observed.  Broilers receiving probiotic 
alone were associated with a reduction (P<0.05) in FCR during the withdrawal period. 
This data is similar to work previously published describing positive correlation with 
respect to performance parameters in broilers receiving probiotic administration (Gao et 
al., 2008; Awad et al., 2009).   
The trial described in Chapter V had a similar experimental design as the 
previous two trials, but included an ionophore (monensin) in the diet of select 
experimental groups and also a different route of application for the evaluated probiotic.  
A feed-based probiotic, comprised of the same culture evaluated in trials described in 
Chapters III and IV but modified for dietary inclusion prior to crumbling/pelleting was 
included in two experimental groups.  This comparison of feed-applied or water-applied 
probiotic application resulted in generally improved performance associated with the 
water application of probiotic in this trial.  An interesting observation of this trial was 
observed with cumulative body weight and FCR when comparing broilers in vaccinated 
with probiotic groups against broilers receiving dietary ionophore administration.  At 
termination of this trial, values for body weight and FCR in broilers from the vaccine + 
probiotic (water) group were improved compared to all other experimental groups, 
including vaccine alone, and were indistinguishable from broilers in ionophore groups.  
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Vaccination has often been compared with anticoccidial use and the results often range 
from negative to variable.  Other reports have shown that using a vaccine to be as good 
if not better for performance when compared to anticoccidial drugs (Danforth, 1998; 
Mathis, 1999; Suo et al., 2006), while others suggest that vaccines do not outperform 
anticoccidials (Williams et al., 1999).  Oocyst output in this trial (Chapter V) supported 
higher challenge levels were achieved through feed delivery when compared to the trial 
described in Chapter IV where litter application of oocysts was performed.  Patterns of 
output were similar to the previous two trials (Chapters III and IV) where vaccinated 
broilers were associated with two early peaks during rearing.  Non-vaccinated broilers, 
again similar to previous observations, were associated with two output peaks later in the 
trial.  
Another area of interest discussed in this thesis relates to the intestinal health 
parameters measured in broilers receiving a clinical challenge of field strain Eimeria to 
test immunity development later in grow-out.  During the trials described in Chapters IV 
and V, a subset of broilers was pulled from the performance trial approximately one 
week prior to termination.  These animals were challenged and reared for seven days to 
evaluate the effects of clinical challenge in broilers from different experimental groups 
in these trials.  General trends supported vaccination as being very effective in reducing 
gross lesion scores, microscopic lesion scores, and weight gain during challenge.  These 
observations were expected and are supported by previous research reporting lesion 
development in vaccinated broilers (Williams, 2003).  Data from the trial described in 
Chapter V generally showed an increase in lesion development associated with the 
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ionophore alone group compared to other experimental groups in this trial, confirming 
that immunity development in these broilers was delayed and ineffective at protecting 
these animals against clinical Eimeria challenge.  Direct effects of probiotic 
administration in minimizing clinical parameters related to infection during Eimeria 
challenge were observed.  In the trial described in Chapter IV, probiotic administration 
alone reduced gross and microscopic lesion development during challenge. 
Taken together, the data presented in Chapters III, IV, and V of this thesis 
suggests that probiotic administration improves coccidiosis vaccine efficacy and reduces 
the negative effects of challenge by field strain Eimeria.  These findings suggest that 
simultaneous probiotic and vaccine administration can improve performance and 
intestinal health parameters during periods of clinical coccidiosis invasion.  More 
research needs to be performed to validate and extend these findings to assist with 
improving vaccine efficacy in the future.  The future of the poultry industry will rely 
heavily on research and development of alternative methods of coccidiosis control to 
ensure that growers are well equipped to minimize and control coccidiosis within the 
environment of commercial poultry production.  
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